

Cancer/testis antigens, gametogenesis and cancer

Nature Reviews Cancer

5, 615-625

DOI: [10.1038/nrc1669](https://doi.org/10.1038/nrc1669)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. <i>Biochemical and Biophysical Research Communications</i> , 2005, 335, 1293-1304.	1.0	66
2	The Human T Cell Response to Melanoma Antigens. <i>Advances in Immunology</i> , 2006, 92, 187-224.	1.1	56
3	NY-ESO-1: Review of an Immunogenic Tumor Antigen. <i>Advances in Cancer Research</i> , 2006, 95, 1-30.	1.9	311
4	Dosage compensation in mammals: fine-tuning the expression of the X chromosome. <i>Genes and Development</i> , 2006, 20, 1848-1867.	2.7	439
5	Promises and Limitations of Murine Models in the Development of Anticancer T-Cell Vaccines. <i>International Reviews of Immunology</i> , 2006, 25, 269-295.	1.5	15
6	Is there a role for immunotherapy in hepatocellular carcinoma?. <i>Digestive and Liver Disease</i> , 2006, 38, 221-225.	0.4	17
7	Directed evolution for improved secretion of cancer testis antigen NY-ESO-1 from yeast. <i>Protein Expression and Purification</i> , 2006, 48, 232-242.	0.6	33
8	Genomic Imprinting and Cancer: From Primordial Germ Cells to Somatic Cells. <i>Scientific World Journal, The</i> , 2006, 6, 1888-1910.	0.8	31
9	Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. <i>Blood</i> , 2006, 108, 4109-4117.	0.6	177
10	Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens. <i>Melanoma Research</i> , 2006, 16, 347-355.	0.6	14
11	Stem cells, senescence, neosis and self-renewal in cancer. <i>Cancer Cell International</i> , 2006, 6, 25.	1.8	108
12	Directions in the immune targeting of cancer: Lessons learned from the cancer testis Ag NY-ESO-1. <i>Immunology and Cell Biology</i> , 2006, 84, 303-317.	1.0	96
14	Immunotherapy of malignant melanoma â€” Basic principles and novel therapeutic approaches. <i>JDDG - Journal of the German Society of Dermatology</i> , 2006, 4, 635-644.	0.4	4
16	Die Immuntherapie des malignen Melanoms â€” Grundlagen und neue Therapieansatze. <i>JDDG - Journal of the German Society of Dermatology</i> , 2006, 4, --.	0.4	0
17	The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2006, 134, 238-239.	1.2	15
18	More on 'universal' versus 'selected' screening for thrombophilia: the hidden costs of false-positive diagnosis. <i>British Journal of Haematology</i> , 2006, 134, 239-240.	1.2	8
19	Expression of Y-box-binding protein dbpC/contrin, a potentially new cancer/testis antigen. <i>British Journal of Cancer</i> , 2006, 94, 710-716.	2.9	17
20	Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. <i>British Journal of Cancer</i> , 2006, 94, 1864-1873.	2.9	54

#	ARTICLE	IF	CITATIONS
21	Genomic Instability and Tumor Stem Cells. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1214-1216.	0.3	30
22	PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. <i>Leukemia</i> , 2006, 20, 2172-2174.	3.3	27
23	Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. <i>Oncogene</i> , 2006, 25, 6975-6985.	2.6	110
24	Epigenetics and the plasticity of differentiation in normal and cancer stem cells. <i>Oncogene</i> , 2006, 25, 7663-7672.	2.6	94
25	Expression profiling of autoimmune regulator AIRE mRNA in a comprehensive set of human normal and neoplastic tissues. <i>Immunology Letters</i> , 2006, 106, 172-179.	1.1	31
26	Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL). <i>Leukemia Research</i> , 2006, 30, 883-889.	0.4	34
28	Therapeutic cancer vaccines. <i>Current Opinion in Immunology</i> , 2006, 18, 201-205.	2.4	132
29	Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. <i>Biochemical Pharmacology</i> , 2006, 72, 1577-1588.	2.0	82
30	Sperm protein 17 is expressed in human nervous system tumours. <i>BMC Cancer</i> , 2006, 6, 23.	1.1	36
31	Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. <i>BMC Cancer</i> , 2006, 6, 6.	1.1	84
32	Unbalanced alternative splicing and its significance in cancer. <i>BioEssays</i> , 2006, 28, 378-386.	1.2	278
33	Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. <i>Journal of Cellular Biochemistry</i> , 2006, 98, 1037-1043.	1.2	38
34	Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2006, 118, 2522-2528.	2.3	47
35	A Potential Role for Epigenetic Modulatory Drugs in the Enhancement of Cancer/Germ-Line Antigen Vaccine Efficacy. <i>Epigenetics</i> , 2006, 1, 116-120.	1.3	89
36	Cancer-testis antigens in tumor biology and immunotherapy. <i>Cancer Biology and Therapy</i> , 2006, 5, 1226-1227.	1.5	7
37	PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase, a Putative Cancer/Testis Antigen with an Oncogenic Activity in Breast Cancer. <i>Cancer Research</i> , 2006, 66, 9186-9195.	0.4	164
38	A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies. <i>PLoS Medicine</i> , 2006, 3, e486.	3.9	228
39	De novo Induction of a Cancer/Testis Antigen by 5-Aza-2-Deoxycytidine Augments Adoptive Immunotherapy in a Murine Tumor Model. <i>Cancer Research</i> , 2006, 66, 1105-1113.	0.4	133

#	ARTICLE	IF	CITATIONS
40	Characterization and Expression of CT45 in Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 4804-4811.	3.2	27
41	Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura. <i>Clinical Cancer Research</i> , 2006, 12, 5777-5785.	3.2	214
42	Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells. <i>Clinical Cancer Research</i> , 2006, 12, 398-404.	3.2	32
43	The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes. <i>Human Molecular Genetics</i> , 2006, 15, 2392-2399.	1.4	24
44	MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 11160-11165.	3.3	221
45	Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 18066-18071.	3.3	32
46	Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 5442-5447.	3.2	81
47	Recent Advances and Current Challenges in Tumor Immunology and Immunotherapy. <i>Molecular Therapy</i> , 2007, 15, 1065-1071.	3.7	29
48	Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8947-8952.	3.3	275
49	Elicitation of T Cell Responses to Histologically Unrelated Tumors by Immunization with the Novel Cancer-Testis Antigen, Brother of the Regulator of Imprinted Sites. <i>Journal of Immunology</i> , 2007, 178, 566-573.	0.4	28
50	Enhancement of Human Melanoma Antigen Expression by IFN- γ . <i>Journal of Immunology</i> , 2007, 179, 2134-2142.	0.4	25
51	Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression. <i>Clinical Cancer Research</i> , 2007, 13, 1713-1719.	3.2	64
52	Identification of a Novel Cancer-Testis Antigen CRT2 Frequently Expressed in Various Cancers Using Representational Differential Analysis. <i>Clinical Cancer Research</i> , 2007, 13, 6267-6274.	3.2	12
53	Fundamental Differences in Cell Cycle Deregulation in Human Papillomavirus-Positive and Human Papillomavirus-Negative Head/Neck and Cervical Cancers. <i>Cancer Research</i> , 2007, 67, 4605-4619.	0.4	407
54	Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. <i>Cancer Research</i> , 2007, 67, 2982-2989.	0.4	236
55	MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. <i>Human Reproduction</i> , 2007, 22, 953-960.	0.4	61
56	Immunologic markers of cancer progression and prognosis. <i>Expert Opinion on Medical Diagnostics</i> , 2007, 1, 439-450.	1.6	0
57	New Technologies Used in the Study of Human Melanoma. <i>International Review of Cytology</i> , 2007, 261, 247-286.	6.2	5

#	ARTICLE	IF	CITATIONS
58	Anti-Tumor Vaccines in Head and Neck Cancer: Targeting Immune Responses to the Tumor. <i>Current Cancer Drug Targets</i> , 2007, 7, 633-642.	0.8	24
59	Serine-Arginine Protein Kinase 1 Overexpression Is Associated with Tumorigenic Imbalance in Mitogen-Activated Protein Kinase Pathways in Breast, Colonic, and Pancreatic Carcinomas. <i>Cancer Research</i> , 2007, 67, 2072-2080.	0.4	140
61	The conserved transcriptome in human and rodent male gametogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8346-8351.	3.3	234
62	CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3967-3972.	3.3	445
63	Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis. <i>Journal of Immunology</i> , 2007, 178, 3307-3315.	0.4	109
64	A Placenta-Specific Gene Ectopically Activated in Many Human Cancers Is Essentially Involved in Malignant Cell Processes. <i>Cancer Research</i> , 2007, 67, 9528-9534.	0.4	82
65	MAGE-A, mMage-b, and MAGE-C Proteins Form Complexes with KAP1 and Suppress p53-Dependent Apoptosis in MAGE-Positive Cell Lines. <i>Cancer Research</i> , 2007, 67, 9954-9962.	0.4	235
66	Tumor Antigen-Based Immunotherapy and Immunoprevention of Cancer. <i>International Archives of Allergy and Immunology</i> , 2007, 142, 179-189.	0.9	22
67	Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 13122-13127.	3.3	49
68	Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. <i>Haematologica</i> , 2007, 92, 153-162.	1.7	54
69	Utilization of Chromatin Remodeling Agents for Lung Cancer Therapy. <i>Cancer Journal (Sudbury, Mass)</i> 10:101-106 (2004)	1.9	10
70	Cancer testis antigen expression in primary and recurrent vulvar cancer: Association with prognostic factors. <i>European Journal of Cancer</i> , 2007, 43, 2621-2627.	1.3	28
71	Cancer stem cells and human malignant melanoma. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 39-55.	1.5	181
72	General Principles of Tumor Immunotherapy. , 2007, , .		3
73	Current Immunotherapeutic Strategies in Malignant Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2007, 16, 945-973.	0.6	5
74	Hypomethylation and Aberrant Expression of the Glioma Pathogenesis-Related 1 Gene in Wilms Tumors. <i>Neoplasia</i> , 2007, 9, 970-978.	2.3	40
75	Concise Review: Cancer/Testis Antigens, Stem Cells, and Cancer. <i>Stem Cells</i> , 2007, 25, 707-711.	1.4	122
76	The Role of DNA Methylation in the Development and Progression of Lung Adenocarcinoma. <i>Disease Markers</i> , 2007, 23, 5-30.	0.6	80

#	ARTICLE	IF	CITATIONS
77	Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. <i>International Journal of Cancer</i> , 2007, 120, 67-74.	2.3	70
78	Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. <i>International Journal of Cancer</i> , 2007, 120, 337-343.	2.3	61
79	The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. <i>International Journal of Cancer</i> , 2007, 120, 2635-2642.	2.3	31
80	Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. <i>International Journal of Cancer</i> , 2007, 121, 301-307.	2.3	50
81	Inducible expression of a prostate cancer-associated testis antigen, SSX2, following treatment with a DNA methylation inhibitor. <i>Prostate</i> , 2007, 67, 1781-1790.	1.2	48
82	Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells. <i>Oncogene</i> , 2007, 26, 1533-1545.	2.6	27
83	Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. <i>Oncogene</i> , 2007, 26, 4394-4403.	2.6	62
84	Oncoimmunology: Some fundamental problems of cancer immunotherapy. <i>Molecular Biology</i> , 2007, 41, 316-328.	0.4	3
85	Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. <i>Nature Genetics</i> , 2007, 39, 457-466.	9.4	1,922
86	Select Cancer Testes Antigens of the MAGE-A, -B, and -C Families Are Expressed in Mast Cell Lines and Promote Cell Viability In Vitro and In Vivo. <i>Journal of Investigative Dermatology</i> , 2007, 127, 267-275.	0.3	59
87	Epigenetic Control of MAGE Gene Expression by the KIT Tyrosine Kinase. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2123-2128.	0.3	29
88	Stability and flexibility of epigenetic gene regulation in mammalian development. <i>Nature</i> , 2007, 447, 425-432.	13.7	1,728
89	Cancer-testis antigens in haematological malignancies. <i>British Journal of Haematology</i> , 2007, 136, 769-776.	1.2	43
90	Immunodeficiency and immunotherapy in multiple myeloma. <i>British Journal of Haematology</i> , 2007, 138, 563-579.	1.2	297
91	Expression of two testis-specific genes, TSGA10 and SYCP3, in different cancers regarding to their pathological features. <i>Cancer Detection and Prevention</i> , 2007, 31, 296-302.	2.1	40
92	Toward Understanding the Core Meiotic Transcriptome in Mammals and Its Implications for Somatic Cancer. <i>Annals of the New York Academy of Sciences</i> , 2007, 1120, 1-15.	1.8	17
93	Rapid evolution of cancer/testis genes on the X chromosome. <i>BMC Genomics</i> , 2007, 8, 129.	1.2	80
94	Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 839-847.	2.0	28

#	ARTICLE	IF	CITATIONS
95	Towards progress on DNA vaccines for cancer. Cellular and Molecular Life Sciences, 2007, 64, 2391-2403.	2.4	43
96	Selective cancer-germline gene expression in pediatric brain tumors. Journal of Neuro-Oncology, 2008, 88, 273-280.	1.4	24
97	Recent duplication and positive selection of the GAGE gene family. Genetica, 2008, 133, 31-35.	0.5	15
98	Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunology, Immunotherapy, 2008, 57, 1429-1437.	2.0	40
99	Aberrant hypomethylation of the cancer testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Annals of Hematology, 2008, 87, 809-818.	0.8	52
100	Expression of BORIS in melanoma: Lack of association with MAGE-A1 activation. International Journal of Cancer, 2008, 122, 777-784.	2.3	57
101	Plac1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patients. International Journal of Cancer, 2008, 122, 2038-2043.	2.3	46
102	Antibodies against the cancer testis antigen CTSP1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical recurrence. International Journal of Cancer, 2008, 122, 2385-2390.	2.3	13
103	Antigens for cancer immunotherapy. Seminars in Immunology, 2008, 20, 286-295.	2.7	147
104	Infrequent and low expression of cancer testis antigens located on the X chromosome in colorectal cancer: Implications for immunotherapy in South African populations. Biotechnology Journal, 2008, 3, 1417-1423.	1.8	8
105	Involvement of c-Abl and D40 (AF15Q14/CASC5) proteins in the regulation of cell proliferation and cancer. Cell and Tissue Biology, 2008, 2, 354-359.	0.2	6
106	MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy. American Journal of Obstetrics and Gynecology, 2008, 198, 99.e1-99.e7.	0.7	40
107	MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia, 2008, 22, 1646-1648.	3.3	28
108	Cancer-associated antigens and antigen arrays in serological diagnostics of malignant tumors. Biochemistry (Moscow), 2008, 73, 562-572.	0.7	12
109	DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Therapy, 2008, 15, 61-64.	2.3	27
110	An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. Tissue Antigens, 2008, 71, 187-192.	1.0	57
111	Novel BRCA2-interacting protein BJ-HCC-20A inhibits the induction of apoptosis in response to DNA damage. Cancer Science, 2008, 99, 747-754.	1.7	9
112	MAGE-C1/CT-7 expression in plasma cell myeloma: Sub-cellular localization impacts on clinical outcome. Cancer Science, 2008, 99, 720-725.	1.7	42

#	ARTICLE	IF	CITATIONS
113	Different expression of MAGE-A-antigens in foetal and adult keratinocyte cell lines. <i>Oral Oncology</i> , 2008, 44, 628-633.	0.8	12
114	The Specific Immune Response to Tumor Antigen CP1 and Its Correlation With Improved Survival in Colon Cancer Patients. <i>Gastroenterology</i> , 2008, 134, 998-1006.	0.6	43
115	Breast cancer stem cells: implications for therapy of breast cancer. <i>Breast Cancer Research</i> , 2008, 10, 210.	2.2	109
116	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20410-20415.	3.3	322
117	Cancer: Shift of the paradigm. <i>Medical Hypotheses</i> , 2008, 71, 839-850.	0.8	10
118	Common Themes of Dedifferentiation in Somatic Cell Reprogramming and Cancer. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2008, 73, 171-174.	2.0	61
119	Biology and regulation of ectoplasmic specialization, an atypical adherens junction type, in the testis. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2008, 1778, 692-708.	1.4	171
120	Next Generation of Immunotherapy for Melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3445-3455.	0.8	215
121	Distinct GAGE and MAGE-A expression during early human development indicate specific roles in lineage differentiation. <i>Human Reproduction</i> , 2008, 23, 2194-2201.	0.4	52
122	Sperm-Associated Antigen 9 Is Associated With Tumor Growth, Migration, and Invasion in Renal Cell Carcinoma. <i>Cancer Research</i> , 2008, 68, 8240-8248.	0.4	72
123	A Conserved E2F6-Binding Element in Murine Meiosis-Specific Gene Promoters ¹ . <i>Biology of Reproduction</i> , 2008, 79, 921-930.	1.2	34
124	DNA Hypomethylation Arises Later in Prostate Cancer Progression than CpG Island Hypermethylation and Contributes to Metastatic Tumor Heterogeneity. <i>Cancer Research</i> , 2008, 68, 8954-8967.	0.4	255
125	Genome-wide analysis of cancer/testis gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20422-20427.	3.3	295
126	Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells. <i>Journal of Immunology</i> , 2008, 181, 3099-3107.	0.4	604
127	Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 1650-1655.	3.3	149
128	Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant. <i>Journal of Immunology</i> , 2008, 181, 776-784.	0.4	230
129	Epidermal Growth Factor-Dependent Phosphorylation and Ubiquitinylation of MAGE-11 Regulates Its Interaction with the Androgen Receptor. <i>Molecular and Cellular Biology</i> , 2008, 28, 1947-1963.	1.1	60
130	ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3291-3298.	3.2	32

#	ARTICLE	IF	CITATIONS
131	Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. <i>Clinical Cancer Research</i> , 2008, 14, 7624-7634.	3.2	247
132	Genome-Wide Expression of Azoospermia Testes Demonstrates a Specific Profile and Implicates ART3 in Genetic Susceptibility. <i>PLoS Genetics</i> , 2008, 4, e26.	1.5	97
133	The Evolution of Epigenetic Regulators CTCF and BORIS/CTCF in Amniotes. <i>PLoS Genetics</i> , 2008, 4, e1000169.	1.5	72
134	Integral Protein Microarrays for the Identification of Lung Cancer Antigens in Sera That Induce a Humoral Immune Response. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 268-281.	2.5	58
135	Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission. <i>Clinical Cancer Research</i> , 2008, 14, 2740-2748.	3.2	98
136	Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3283-3290.	3.2	89
137	Rapid tolerization of virus-activated tumor-specific CD8 ⁺ T cells in prostate tumors of TRAMP mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13003-13008.	3.3	65
138	Efficient Identification of a Novel Cancer/Testis Antigen for Immunotherapy Using Three-Step Microarray Analysis. <i>Cancer Research</i> , 2008, 68, 1074-1082.	0.4	42
139	Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. <i>Journal of Neurosurgery: Pediatrics</i> , 2008, 1, 305-313.	0.8	40
140	Selective POTE Paralogs on Chromosome 2 are Expressed in Human Embryonic Stem Cells. <i>Stem Cells and Development</i> , 2008, 17, 325-332.	1.1	19
141	MAGE-B2 Autoantibody: A New Biomarker for Pediatric Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2008, 35, 2430-2438.	1.0	12
142	Differential pattern of CD4 ⁺ and CD8 ⁺ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. <i>Blood</i> , 2008, 112, 3362-3372.	0.6	44
143	Cancer/testis genes expression in human melanoma cell lines. <i>Melanoma Research</i> , 2008, 18, 303-313.	0.6	34
146	Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties. <i>PLoS ONE</i> , 2008, 3, e3077.	1.1	373
147	Early findings of a novel established molecular diagnostic technique for the prediction of malignant transformation in leukoplakia. <i>Molecular Medicine Reports</i> , 2009, 02, 947-52.	1.1	3
149	Integrative Discovery of Epigenetically Derepressed Cancer Testis Antigens in NSCLC. <i>PLoS ONE</i> , 2009, 4, e8189.	1.1	64
151	Epigenetically regulated tumor-associated antigens in melanoma. <i>Expert Review of Dermatology</i> , 2009, 4, 145-154.	0.3	1
152	Increased Expression of Androgen Receptor Coregulator MAGE-11 in Prostate Cancer by DNA Hypomethylation and Cyclic AMP. <i>Molecular Cancer Research</i> , 2009, 7, 523-535.	1.5	112

#	ARTICLE	IF	CITATIONS
153	Activation of Meiosis-Specific Genes Is Associated with Depolyploidization of Human Tumor Cells following Radiation-Induced Mitotic Catastrophe. <i>Cancer Research</i> , 2009, 69, 2296-2304.	0.4	107
154	Emerging Therapeutic Targets in Non-Small Cell Lung Cancer. <i>Proceedings of the American Thoracic Society</i> , 2009, 6, 218-223.	3.5	18
155	CT-X antigen expression in human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 13493-13498.	3.3	92
156	Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 2166-2173.	3.2	119
157	New hypotheses for large-scale epigenome alterations in somatic cancer cells: a role for male germ-cell-specific regulators. <i>Epigenomics</i> , 2009, 1, 153-161.	1.0	18
158	Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen. <i>Clinical Cancer Research</i> , 2009, 15, 3406-3415.	3.2	38
159	Bioinformatics construction of the human cell surfaceome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16752-16757.	3.3	119
160	A transcriptomic analysis of human centromeric and pericentric sequences in normal and tumor cells. <i>Nucleic Acids Research</i> , 2009, 37, 6340-6354.	6.5	99
161	Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 1343-1352.	3.2	70
162	Distinct Roles for Histone Methyltransferases G9a and GLP in Cancer Germ-Line Antigen Gene Regulation in Human Cancer Cells and Murine Embryonic Stem Cells. <i>Molecular Cancer Research</i> , 2009, 7, 851-862.	1.5	50
163	A Long, Naturally Presented Immunodominant Epitope from NY-ESO-1 Tumor Antigen: Implications for Cancer Vaccine Design. <i>Cancer Research</i> , 2009, 69, 1046-1054.	0.4	48
164	Ultrahigh spacing tissue arrays for screening hybridoma by immunohistochemistry. <i>Journal of Immunological Methods</i> , 2009, 343, 130-133.	0.6	1
165	Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells. <i>BMC Cancer</i> , 2009, 9, 323.	1.1	26
166	Characterization of a novel rat gene RTAP2a, screened by cross-reactive SEREX, restrictedly expressed in testis. <i>Journal of Bioscience and Bioengineering</i> , 2009, 107, 589-595.	1.1	4
167	Frequent expression of the novel cancer testis antigen MAGEC2/CT10 in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2009, 124, 352-357.	2.3	63
168	Identification of CCDC62 as a novel cancer/testis antigen and its immunogenicity. <i>International Journal of Cancer</i> , 2009, 124, 2347-2352.	2.3	18
169	Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer. <i>International Journal of Cancer</i> , 2009, 124, 2893-2898.	2.3	53
170	High frequency of MAGEA4 and MAGEA9 expression in high-risk bladder cancer. <i>International Journal of Cancer</i> , 2009, 125, 1365-1371.	2.3	77

#	ARTICLE	IF	CITATIONS
171	Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. <i>Cancer</i> , 2009, 115, 2671-2683.	2.0	56
172	Small interfering RNA-mediated down-regulation of <i>SPAG9</i> inhibits cervical tumor growth. <i>Cancer</i> , 2009, 115, 5688-5699.	2.0	27
173	Expression of Cancer-Testis Antigens MAGE-A3/6 and NY-ESO-1 in Non-Small-Cell Lung Carcinomas and Their Relationship with Immune Cell Infiltration. <i>Lung</i> , 2009, 187, 401-411.	1.4	64
174	Targets for active immunotherapy against pediatric solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 831-841.	2.0	10
175	Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1635-1646.	2.0	63
176	Vaccination with Human Pluripotent Stem Cells Generates a Broad Spectrum of Immunological and Clinical Responses Against Colon Cancer. <i>Stem Cells</i> , 2009, 27, 3103-3111.	1.4	76
177	Analysis of expression profiles of MAGE-A antigens in oral squamous cell carcinoma cell lines. <i>Head & Face Medicine</i> , 2009, 5, 10.	0.8	14
178	Cancer/testis (CT) antigens: Potential targets for immunotherapy. <i>Cancer Science</i> , 2009, 100, 2014-2021.	1.7	478
179	Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 396-407.	1.2	29
180	Melanoma-initiating cells: a compass needed. <i>EMBO Reports</i> , 2009, 10, 965-972.	2.0	17
181	Carcinogenesis: Evolution of concepts. <i>Biochemistry (Moscow)</i> , 2009, 74, 353-361.	0.7	8
182	Developmental programming of CpG island methylation profiles in the human genome. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 564-571.	3.6	345
183	Serum autoantibodies as biomarkers for early cancer detection. <i>FEBS Journal</i> , 2009, 276, 6880-6904.	2.2	272
184	RNA interference against Biot2, a novel mouse testis specific gene, inhibits the growth of tumor cells. <i>Cellular and Molecular Biology Letters</i> , 2009, 14, 363-76.	2.7	3
185	Scanning the Cell Surface Proteome of Cancer Cells and Identification of Metastasis-Associated Proteins Using a Subtractive Immunization Strategy. <i>Journal of Proteome Research</i> , 2009, 8, 5048-5059.	1.8	12
186	Identification of FAM46D as a novel cancer/testis antigen using EST data and serological analysis. <i>Genomics</i> , 2009, 94, 153-160.	1.3	23
187	Immunotherapy for adenoid cystic carcinoma of salivary glands: Cancer/testis antigens and 5-aza-2'-deoxycytidine. <i>Medical Hypotheses</i> , 2009, 73, 768-769.	0.8	3
188	CD30. , 2008, , 544-544.		0

#	ARTICLE	IF	CITATIONS
189	CD15. , 2008, , 540-540.		0
190	Catastrophe Promoter. , 2008, , 526-526.		0
191	Epigenetic Modulation of Cancer-Germline Antigen Gene Expression in Tumorigenic Human Mesenchymal Stem Cells. American Journal of Pathology, 2009, 175, 314-323.	1.9	24
192	Very Small Embryonic/Epiblast-Like Stem Cells. American Journal of Pathology, 2009, 174, 1985-1992.	1.9	48
193	Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy, 2009, 11, 912-922.	0.3	35
195	Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 2009, 114, 535-546.	0.6	1,280
196	Epigenetics in Human Melanoma. Cancer Control, 2009, 16, 200-218.	0.7	87
197	Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience. Current Pharmaceutical Design, 2009, 15, 950-956.	0.9	7
198	Aberrant DNA methylation in malignant melanoma. Melanoma Research, 2010, 20, 253-265.	0.6	88
199	Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica, 2010, 95, 785-793.	1.7	87
200	CD8+ T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect. Haematologica, 2010, 95, 1572-1578.	1.7	16
201	Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood, 2010, 116, 1908-1918.	0.6	304
202	Novel drugs for the treatment of multiple myeloma. Haematologica, 2010, 95, 702-704.	1.7	15
203	Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors. Cancer Immunology, Immunotherapy, 2010, 59, 183-193.	2.0	15
204	Cancer: evolutionary, genetic and epigenetic aspects. Clinical Epigenetics, 2010, 1, 85-100.	1.8	14
205	Epiblast/Germ Line Hypothesis of Cancer Development Revisited: Lesson from the Presence of Oct-4+ Cells in Adult Tissues. Stem Cell Reviews and Reports, 2010, 6, 307-316.	5.6	70
206	mRNA expression of the XAGE-1 gene in human acute leukemia. International Journal of Hematology, 2010, 91, 209-212.	0.7	3
207	Identification of a novel human cancer/testis gene MAEL that is regulated by DNA methylation. Molecular Biology Reports, 2010, 37, 2355-2360.	1.0	36

#	ARTICLE	IF	CITATIONS
208	Review: Sex Chromosome Evolution and the Expression of Sex-Specific Genes in the Placenta. <i>Placenta</i> , 2010, 31, S27-S32.	0.7	60
209	Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. <i>BMC Cancer</i> , 2010, 10, 163.	1.1	41
210	A novel spliced fusion of MLL with CT45A2 in a pediatric biphenotypic acute leukemia. <i>BMC Cancer</i> , 2010, 10, 518.	1.1	9
211	Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma. <i>Pathology Research and Practice</i> , 2010, 206, 695-699.	1.0	13
212	The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. <i>Leukemia Research</i> , 2010, 34, 899-905.	0.4	164
213	Immunity to stemness genes in human cancer. <i>Current Opinion in Immunology</i> , 2010, 22, 245-250.	2.4	30
214	Expression of cancer/testis antigens in prostate cancer is associated with disease progression. <i>Prostate</i> , 2010, 70, 1778-1787.	1.2	60
215	3-Methylcholanthrene-induced transforming growth factor β -producing carcinomas, but not sarcomas, are refractory to regulatory T cell-depletion therapy. <i>Cancer Science</i> , 2010, 101, 855-861.	1.7	9
216	Elevated expression levels of testis-specific genes <i>TEX101</i> and <i>SPATA19</i> in basal cell carcinoma and their correlation with clinical and pathological features. <i>British Journal of Dermatology</i> , 2010, 162, 772-779.	1.4	47
217	Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. <i>Oncogene</i> , 2010, 29, 3650-3664.	2.6	245
218	Genetics and epigenetics of the X chromosome. <i>Annals of the New York Academy of Sciences</i> , 2010, 1214, E18-33.	1.8	43
219	Targets and dynamics of promoter DNA methylation during early mouse development. <i>Nature Genetics</i> , 2010, 42, 1093-1100.	9.4	527
220	Tumor Antigen Presentation by Dendritic Cells. <i>Critical Reviews in Immunology</i> , 2010, 30, 345-386.	1.0	51
221	Initiation of Meiotic Recombination in Mammals. <i>Genes</i> , 2010, 1, 521-549.	1.0	15
222	Expression of the Y-Encoded TSPY is Associated with Progression of Prostate Cancer. <i>Genes</i> , 2010, 1, 283-293.	1.0	18
223	BORIS (CTCF) Is Not Expressed in Most Human Breast Cell Lines and High Grade Breast Carcinomas. <i>PLoS ONE</i> , 2010, 5, e9738.	1.1	22
224	Frequent MAGE Mutations in Human Melanoma. <i>PLoS ONE</i> , 2010, 5, e12773.	1.1	22
225	The Structural Complexity of the Human BORIS Gene in Gametogenesis and Cancer. <i>PLoS ONE</i> , 2010, 5, e13872.	1.1	57

#	ARTICLE	IF	CITATIONS
226	Martini: using literature keywords to compare gene sets. <i>Nucleic Acids Research</i> , 2010, 38, 26-38.	6.5	51
227	Mage-A Cancer/Testis Antigens Inhibit p53 Function by Blocking Its Interaction with Chromatin. <i>Cancer Research</i> , 2010, 70, 10362-10370.	0.4	126
228	Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2010, 16, 3562-3570.	3.2	51
229	Deficiency in the Multicopy <i>Sycp3</i> -Like X-Linked Genes <i>Slx</i> and <i>Slxl1</i> Causes Major Defects in Spermatid Differentiation. <i>Molecular Biology of the Cell</i> , 2010, 21, 3497-3505.	0.9	58
230	Knockdown of Cancer Testis Antigens Modulates Neural Stem Cell Marker Expression in Glioblastoma Tumor Stem Cells. <i>Journal of Biomolecular Screening</i> , 2010, 15, 830-839.	2.6	11
231	Tumor Antigen Acrosin Binding Protein Normalizes Mitotic Spindle Function to Promote Cancer Cell Proliferation. <i>Cancer Research</i> , 2010, 70, 7652-7661.	0.4	58
232	Dnmt3b recruitment through E2F6 transcriptional repressor mediates germ-line gene silencing in murine somatic tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 9281-9286.	3.3	118
233	Ectopic Expression of Germline Genes Drives Malignant Brain Tumor Growth in <i>Drosophila</i> . <i>Science</i> , 2010, 330, 1824-1827.	6.0	252
234	Role of epigenomics in ovarian and endometrial cancers. <i>Epigenomics</i> , 2010, 2, 419-447.	1.0	46
235	Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers. <i>Clinical Cancer Research</i> , 2010, 16, 4607-4615.	3.2	10
236	Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15187-15192.	3.3	21
237	Plasma Membrane Proteomics and Its Application in Clinical Cancer Biomarker Discovery. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 1369-1382.	2.5	142
238	RECENT PROGRESS AND FUTURE DIRECTIONS USING ENGINEERED T CELLS FOR THE TREATMENT OF CANCER. <i>Gene Therapy and Regulation</i> , 2010, 05, 67-80.	0.3	1
239	Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 3093-3098.	3.3	35
240	Androgen receptor molecular biology and potential targets in prostate cancer. <i>Therapeutic Advances in Urology</i> , 2010, 2, 105-117.	0.9	37
241	Chromosomal Redistribution of Male-Biased Genes in Mammalian Evolution with Two Bursts of Gene Gain on the X Chromosome. <i>PLoS Biology</i> , 2010, 8, e1000494.	2.6	182
242	Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy. <i>Leukemia and Lymphoma</i> , 2010, 51, 1543-1549.	0.6	6
243	Cancer germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1061-1075.	1.4	19

#	ARTICLE	IF	CITATIONS
244	Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. <i>Future Oncology</i> , 2010, 6, 717-732.	1.1	97
245	Germ Cell Genes and Cancer. <i>Science</i> , 2010, 330, 1761-1762.	6.0	17
246	Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. <i>Expert Review of Vaccines</i> , 2010, 9, 617-629.	2.0	20
247	MAGE-RING Protein Complexes Comprise a Family of E3 Ubiquitin Ligases. <i>Molecular Cell</i> , 2010, 39, 963-974.	4.5	388
248	aMAGEing New Players Enter the RING to Promote Ubiquitylation. <i>Molecular Cell</i> , 2010, 39, 835-837.	4.5	11
249	Expression, purification and characterization of the cancer-germline antigen GAGE12I: A candidate for cancer immunotherapy. <i>Protein Expression and Purification</i> , 2010, 73, 217-222.	0.6	4
250	Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients. <i>Vaccine</i> , 2010, 28, 5338-5346.	1.7	7
251	Expression of The Embryonic Stem Cell Transcription Factor SOX2 in Human Skin. <i>American Journal of Pathology</i> , 2010, 176, 903-913.	1.9	97
252	Marsupial Genetics and Genomics. , 2010, , .		5
253	Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention?. <i>Epigenomics</i> , 2011, 3, 235-243.	1.0	45
254	Malignant Melanoma. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 77-86.	3.3	11
255	Immunotherapy for Metastatic Solid Cancers. <i>Advances in Surgery</i> , 2011, 45, 341-360.	0.6	71
256	Cancer epigenetics: above and beyond. <i>Toxicology Mechanisms and Methods</i> , 2011, 21, 275-288.	1.3	82
257	GnRH Agonists. , 2011, , 1576-1576.		0
258	Gossypol. , 2011, , 1586-1586.		0
259	Characterization of Intrinsically Disordered Prostate Associated Gene (PAGE5) at Single Residue Resolution by NMR Spectroscopy. <i>PLoS ONE</i> , 2011, 6, e26633.	1.1	20
260	The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. <i>Molecular Oncology</i> , 2011, 5, 164-182.	2.1	281
261	MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors. <i>Modern Pathology</i> , 2011, 24, 829-835.	2.9	39

#	ARTICLE	IF	CITATIONS
262	G2/M Cyclins. , 2011, , 1481-1482.		0
263	Identification of novel small molecules that inhibit proteinâ€“protein interactions between MAGE and KAP-1. Archives of Biochemistry and Biophysics, 2011, 508, 217-221.	1.4	20
264	Sperm-Associated Antigen 9 Is a Novel Biomarker for Colorectal Cancer and Is Involved in Tumor Growth and Tumorigenicity. American Journal of Pathology, 2011, 178, 1009-1020.	1.9	76
265	Expression of dysadherin in the human male reproductive tract and in spermatozoa. Fertility and Sterility, 2011, 96, 554-561.e2.	0.5	8
266	Cancerâ€“testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. European Journal of Cancer, 2011, 47, 460-469.	1.3	49
267	Induced malignant genome reprogramming in somatic cells by testis-specific factors. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2011, 1809, 221-225.	0.9	21
268	Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochemical and Biophysical Research Communications, 2011, 408, 195-201.	1.0	36
269	Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4. Clinical Cancer Research, 2011, 17, 7058-7066.	3.2	72
270	MAGE-A family: Attractive targets for cancer immunotherapy. Vaccine, 2011, 29, 8496-8500.	1.7	89
271	Neural Stem Cell Biology in Vertebrates and Invertebrates: More Alike than Different?. Neuron, 2011, 70, 719-729.	3.8	106
272	Pattern and clinical significance of cancerâ€“testis gene expression in head and neck squamous cell carcinoma. International Journal of Cancer, 2011, 128, 2625-2634.	2.3	66
273	Melanoma-associated antigen genes â€“ An update. Cancer Letters, 2011, 302, 85-90.	3.2	112
274	Cell transfer immunotherapy for metastatic solid cancerâ€“what clinicians need to know. Nature Reviews Clinical Oncology, 2011, 8, 577-585.	12.5	285
275	Biomarkers for Melanoma Diagnosis and the Technologies Used to Identify Them. , 2011, , .		0
276	Immune-Based Therapies for Sarcoma. Sarcoma, 2011, 2011, 1-7.	0.7	29
277	Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers. PLoS ONE, 2011, 6, e17876.	1.1	84
278	Identification of Methylated Genes Associated with Aggressive Clinicopathological Features in Mantle Cell Lymphoma. PLoS ONE, 2011, 6, e19736.	1.1	32
279	Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy. PLoS ONE, 2011, 6, e21129.	1.1	20

#	ARTICLE	IF	CITATIONS
280	Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients. PLoS ONE, 2011, 6, e21418.	1.1	42
281	NY-ESO-1-Specific Circulating CD4+ T Cells in Ovarian Cancer Patients Are Prevalently TH1 Type Cells Undetectable in the CD25+FOXP3+Treg Compartment. PLoS ONE, 2011, 6, e22845.	1.1	12
283	Sperm-associated Antigens as Targets for Cancer Immunotherapy. Journal of Immunotherapy, 2011, 34, 28-44.	1.2	78
284	Vaccines Targeting the Cancer-testis Antigen SSX-2 Elicit HLA-A2 Epitope-specific Cytolytic T Cells. Journal of Immunotherapy, 2011, 34, 569-580.	1.2	31
285	Vaccines Targeting Cancer Stem Cells. Cancer Journal (Sudbury, Mass), 2011, 17, 397-402.	1.0	15
286	A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica, 2011, 96, 574-582.	1.7	141
287	New Perspectives in Glioma Immunotherapy. Current Pharmaceutical Design, 2011, 17, 2439-2467.	0.9	23
288	The Role of MAGEA2 in Head and Neck Cancer. JAMA Otolaryngology, 2011, 137, 286.	1.5	20
289	Tudor Domain-Containing Protein 4 as a Potential Cancer/Testis Antigen in Liver Cancer. Tohoku Journal of Experimental Medicine, 2011, 224, 41-46.	0.5	16
290	NLS-dependent and insufficient nuclear localization of XAGE-1 splice variants. Oncology Reports, 2011, 25, 1083-9.	1.2	5
291	Melanoma Antigen Encoding Gene-A3 Expression, Its Clinical Significance, and Its Risk of Developing Acute Myeloid Leukemia. Journal of Investigative Medicine, 2011, 59, 1131-1136.	0.7	5
292	Testis cancer gene D40 expression and its relationship with clinicopathological features in infertile men. International Journal of Urology, 2011, 18, 175-179.	0.5	2
293	Studies on the antigenicity of the NKG2D ligand H60a in tumour cells. Immunology, 2011, 133, 197-205.	2.0	2
294	Developing cancer immunotherapies. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 9-13.	0.7	1
295	Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cellular Immunology, 2011, 270, 188-197.	1.4	30
296	Expression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylation. Biotechnology Letters, 2011, 33, 1085-1091.	1.1	9
297	RGS22, a novel cancer/testis antigen, inhibits epithelial cell invasion and metastasis. Clinical and Experimental Metastasis, 2011, 28, 541-549.	1.7	20
298	The melanoma-associated antigen-A3, -A4 genes: relation to the risk and clinicopathological parameters in breast cancer patients. Molecular and Cellular Biochemistry, 2011, 351, 261-268.	1.4	12

#	ARTICLE	IF	CITATIONS
299	Insights on PRAME and osteosarcoma by means of gene expression profiling. <i>Journal of Orthopaedic Science</i> , 2011, 16, 458-466.	0.5	12
300	Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 413-418.	2.0	11
301	Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 999-1007.	2.0	27
302	Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1751-1761.	2.0	7
304	Tumour-associated antigens: considerations for their use in tumour immunotherapy. <i>International Journal of Hematology</i> , 2011, 93, 263-273.	0.7	14
305	When MAGE meets RING: insights into biological functions of MAGE proteins. <i>Protein and Cell</i> , 2011, 2, 7-12.	4.8	46
306	Variants of BORIS minisatellites and relation to prognosis of prostate cancer. <i>Genes and Genomics</i> , 2011, 33, 49-56.	0.5	4
307	Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. <i>Journal of Translational Medicine</i> , 2011, 9, 153.	1.8	71
309	High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. <i>Head and Neck</i> , 2011, 33, 702-707.	0.9	33
310	Detection of melanoma-derived cancer-testis antigen CT16 in patient sera by a novel immunoassay. <i>International Journal of Cancer</i> , 2011, 128, 2382-2392.	2.3	5
311	MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. <i>International Journal of Cancer</i> , 2011, 129, 1137-1148.	2.3	46
312	A phase I study of vaccination with NY-ESO-1 peptide mixed with Picibanil OK432 and Montanide ISA51 in patients with cancers expressing the NY-ESO-1 antigen. <i>International Journal of Cancer</i> , 2011, 129, 2836-2846.	2.3	71
313	Expression and purification of cGMP grade NY-ESO-1 for clinical trials. <i>Biotechnology Progress</i> , 2011, 27, 435-441.	1.3	9
314	DNA Methylation and Nonsmall Cell Lung Cancer. <i>Anatomical Record</i> , 2011, 294, 1787-1795.	0.8	36
315	Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. <i>Spermatogenesis</i> , 2011, 1, 209-220.	0.8	79
316	Expression of MAGE-A antigens is frequent in triple-negative breast cancers but does not correlate with that of basal-like markers. <i>Annals of Oncology</i> , 2011, 22, 986-987.	0.6	6
317	Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview. <i>Current Medicinal Chemistry</i> , 2011, 18, 2893-2903.	1.2	7
318	Personalized Cell Transfer Immunotherapy for B-Cell Malignancies and Solid Cancers. <i>Molecular Therapy</i> , 2011, 19, 1928-1930.	3.7	9

#	ARTICLE	IF	CITATIONS
319	T-Cell Receptor Gene Therapy: Critical Parameters for Clinical Success. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1806-1816.	0.3	38
320	Coordinated Cancer Germline Antigen Promoter and Global DNA Hypomethylation in Ovarian Cancer: Association with the <i>BORIS/CTCF</i> Expression Ratio and Advanced Stage. <i>Clinical Cancer Research</i> , 2011, 17, 2170-2180.	3.2	85
321	The Molecular Basis of Sarcoma. <i>Sarcoma</i> , 2011, 2011, 1-3.	0.7	2
322	Expression and Immunotherapeutic Targeting of the SSX Family of Cancer-Testis Antigens in Prostate Cancer. <i>Cancer Research</i> , 2011, 71, 6785-6795.	0.4	53
323	A TCR Targeting the HLA-A*0201-Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer. <i>Journal of Immunology</i> , 2011, 186, 685-696.	0.4	150
324	BORIS Binding to the Promoters of Cancer Testis Antigens, <i>MAGEA2</i> , <i>MAGEA3</i> , and <i>MAGEA4</i> , Is Associated with Their Transcriptional Activation in Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4267-4276.	3.2	44
325	Cancer-testis antigen expression in triple-negative breast cancer. <i>Annals of Oncology</i> , 2011, 22, 98-103.	0.6	81
326	Testicular Gene Expression in Cryptorchid Boys at Risk of Azoospermia. <i>Sexual Development</i> , 2011, 5, 49-59.	1.1	54
327	Regulation of spermiogenesis, spermiation and blood-testis barrier dynamics: novel insights from studies on <i>Eps8</i> and <i>Arp3</i> . <i>Biochemical Journal</i> , 2011, 435, 553-562.	1.7	102
328	Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. <i>Human Reproduction</i> , 2011, 26, 3232-3243.	0.4	37
329	Regulatory T cells control tolerogenic versus autoimmune response to sperm in vasectomy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 7511-7516.	3.3	79
330	Molecular and Functional Characterization of Mouse <i>S5D-SRCRB</i> : A New Group B Member of the Scavenger Receptor Cysteine-Rich Superfamily. <i>Journal of Immunology</i> , 2011, 186, 2344-2354.	0.4	19
331	The Cancer/Testis Antigen Prostate-associated Gene 4 (<i>PAGE4</i>) Is a Highly Intrinsically Disordered Protein. <i>Journal of Biological Chemistry</i> , 2011, 286, 13985-13994.	1.6	58
332	<i>MAGE-A</i> Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of <i>Bax</i> and Maintenance of <i>Survivin</i> . <i>Clinical Cancer Research</i> , 2011, 17, 4309-4319.	3.2	83
333	Expression of <i>MAGE-A</i> and <i>NY-ESO-1</i> cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study. <i>Croatian Medical Journal</i> , 2011, 52, 171-177.	0.2	16
334	Mechanisms and Evolutionary Patterns of Mammalian and Avian Dosage Compensation. <i>PLoS Biology</i> , 2012, 10, e1001328.	2.6	198
335	<i>LINT</i> , a Novel dL(3)mbt-Containing Complex, Represses Malignant Brain Tumour Signature Genes. <i>PLoS Genetics</i> , 2012, 8, e1002676.	1.5	30
336	Cancer/Testis Antigen <i>MAGE-C1/CT7</i> : New Target for Multiple Myeloma Therapy. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	30

#	ARTICLE	IF	CITATIONS
337	An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens as Potential Immunologic and Clinical Targets in Cancer. <i>Cancer Research</i> , 2012, 72, 6351-6361.	0.4	26
338	Melanoma and Epigenetic Treatment: Past and Future. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 202-209.	0.9	4
339	Trial watch. <i>Oncolmunology</i> , 2012, 1, 1557-1576.	2.1	110
340	Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. <i>British Journal of Cancer</i> , 2012, 107, 116-122.	2.9	77
341	Cancer-testis antigen expression and immunogenicity in AL amyloidosis. <i>Blood Cancer Journal</i> , 2012, 2, e90-e90.	2.8	8
342	Primate-specific Melanoma Antigen-A11 Regulates Isoform-specific Human Progesterone Receptor-B Transactivation. <i>Journal of Biological Chemistry</i> , 2012, 287, 34809-34824.	1.6	32
343	Promoter DNA methylation couples genome-defence mechanisms to epigenetic reprogramming in the mouse germline. <i>Development (Cambridge)</i> , 2012, 139, 3623-3632.	1.2	130
344	Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN- γ Secreting Cells as They Differentiate into Effector T Cells <i>In Vivo</i> . <i>Cancer Research</i> , 2012, 72, 1059-1063.	0.4	33
345	Cell Proliferation in Cutaneous Malignant Melanoma: Relationship with Neoplastic Progression. <i>ISRN Dermatology</i> , 2012, 2012, 1-12.	1.9	20
346	Germ Cell Proteins in Melanoma: Prognosis, Diagnosis, Treatment, and Theories on Expression. <i>Journal of Skin Cancer</i> , 2012, 2012, 1-8.	0.5	12
347	Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.3	8
348	Epigenetic Alterations in Bladder Cancer and Their Potential Clinical Implications. <i>Advances in Urology</i> , 2012, 2012, 1-11.	0.6	24
349	Trial Watch. <i>Oncolmunology</i> , 2012, 1, 306-315.	2.1	70
350	STK31 Maintains the Undifferentiated State of Colon Cancer Cells. <i>Carcinogenesis</i> , 2012, 33, 2044-2053.	1.3	24
351	Multiple Cancer Testis Antigens Function To Support Tumor Cell Mitotic Fidelity. <i>Molecular and Cellular Biology</i> , 2012, 32, 4131-4140.	1.1	69
352	Potential Use of Vaccines in the Primary Prevention of Breast Cancer in High-Risk Patients. <i>Breast Care</i> , 2012, 7, 281-287.	0.8	11
353	Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer. <i>Journal of Immunotherapy</i> , 2012, 35, 131-141.	1.2	45
354	Expression and Clinical Significance of Sperm-Associated Antigen 9 in Patients With Endometrial Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 87-93.	1.2	22

#	ARTICLE	IF	CITATIONS
355	Evaluation of MAGE A1 in oral squamous cell carcinoma. <i>Oncology Reports</i> , 2012, 27, 1843-8.	1.2	9
356	Spontaneous generation of germline characteristics in mouse fibrosarcoma cells. <i>Scientific Reports</i> , 2012, 2, 743.	1.6	12
357	KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer. <i>International Journal of Oncology</i> , 2012, 41, 1820-1826.	1.4	15
358	Pattern of cancer/testis antigen expression in lung cancer patients. <i>International Journal of Molecular Medicine</i> , 2012, 29, 656-662.	1.8	36
359	Synaptonemal complex protein SYCP3 impairs mitotic recombination by interfering with BRCA2. <i>EMBO Reports</i> , 2012, 13, 44-51.	2.0	39
360	Evaluation of MAGE-A expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. <i>International Journal of Oncology</i> , 2012, 41, 1085-1093.	1.4	20
361	A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation. <i>International Journal of Oncology</i> , 2012, 41, 1139-1147.	1.4	9
362	Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. <i>Blood</i> , 2012, 119, 3097-3104.	0.6	65
363	- Characterization of Cancer Cells Using Electrical Impedance Spectroscopy. , 2012, , 584-597.		0
364	HORMAD2/CT46.2, a novel cancer/testis gene, is ectopically expressed in lung cancer tissues. <i>Molecular Human Reproduction</i> , 2012, 18, 599-604.	1.3	29
365	Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity. <i>British Journal of Haematology</i> , 2012, 158, 700-711.	1.2	37
366	Cancer Testes Antigens in Breast Cancer: Biological Role, Regulation, and Therapeutic Applicability. <i>International Reviews of Immunology</i> , 2012, 31, 302-320.	1.5	20
367	Improving the Clinical Efficacy of Cancer Vaccines by Targeting Immune Suppression in Human Tumors. <i>ACS Symposium Series</i> , 2012, , 267-288.	0.5	0
368	Early detection of cancer/testis mRNAs in tumor cells circulating in the peripheral blood of colorectal cancer patients. <i>Molecular Biology</i> , 2012, 46, 687-692.	0.4	2
369	Genetic Consequences of Programmed Genome Rearrangement. <i>Current Biology</i> , 2012, 22, 1524-1529.	1.8	101
370	Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2207-2214.	2.0	15
371	Sperm Protein 17: Is It a Useful Target Antigen in Human Pituitary Adenomas?. <i>Procedia in Vaccinology</i> , 2012, 6, 39-46.	0.4	0
372	The Blood-Testis Barrier and Its Implications for Male Contraception. <i>Pharmacological Reviews</i> , 2012, 64, 16-64.	7.1	673

#	ARTICLE	IF	CITATIONS
373	Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma. <i>British Journal of Ophthalmology</i> , 2012, 96, 451-458.	2.1	25
374	Genetic Regulators of a Pluripotent Adult Stem Cell System in Planarians Identified by RNAi and Clonal Analysis. <i>Cell Stem Cell</i> , 2012, 10, 299-311.	5.2	182
375	Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. <i>Immunotherapy</i> , 2012, 4, 59-75.	1.0	25
376	Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 415-432.	1.1	123
377	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. <i>Cancer Research</i> , 2012, 72, 1672-1682.	0.4	46
378	Global human tissue profiling and protein network analysis reveals distinct levels of transcriptional germline-specificity and identifies target genes for male infertility. <i>Human Reproduction</i> , 2012, 27, 3233-3248.	0.4	82
379	Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome. <i>Cancer Letters</i> , 2012, 321, 18-26.	3.2	23
380	DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy. <i>Developmental Cell</i> , 2012, 22, 38-51.	3.1	384
381	Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. <i>European Journal of Cancer</i> , 2012, 48, 12-23.	1.3	43
382	High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. <i>Medical Oncology</i> , 2012, 29, 1586-1591.	1.2	24
383	Human postmeiotic sex chromatin and its impact on sex chromosome evolution. <i>Genome Research</i> , 2012, 22, 827-836.	2.4	50
384	MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs. <i>Cell Death and Differentiation</i> , 2012, 19, 926-936.	5.0	46
385	The bioinformatics tool box for reproductive biology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1880-1895.	1.8	5
386	MAGE-A antigens as targets in tumour therapy. <i>Cancer Letters</i> , 2012, 324, 126-132.	3.2	73
387	Use of Cancer/Testis Antigens in Immunotherapy: Potential Effect on Mesenchymal Stem Cells. <i>Stem Cells and Cancer Stem Cells</i> , 2012, , 113-119.	0.1	1
388	Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma. <i>Oncology Reports</i> , 2012, 28, 1792-1798.	1.2	25
389	Cancer Testis Antigens: A Novel Target in Lung Cancer. <i>International Reviews of Immunology</i> , 2012, 31, 321-343.	1.5	21
390	Cancer/testis antigens and urological malignancies. <i>Nature Reviews Urology</i> , 2012, 9, 386-396.	1.9	45

#	ARTICLE	IF	CITATIONS
393	MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis. <i>Oncology Reports</i> , 2012, 28, 1498-1502.	1.2	25
394	Potential Role for PAD2 in Gene Regulation in Breast Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e41242.	1.1	82
395	GAGE Cancer-Germline Antigens Are Recruited to the Nuclear Envelope by Germ Cell-Less (GCL). <i>PLoS ONE</i> , 2012, 7, e45819.	1.1	14
396	Implication of DNA Demethylation and Bivalent Histone Modification for Selective Gene Regulation in Mouse Primordial Germ Cells. <i>PLoS ONE</i> , 2012, 7, e46036.	1.1	27
397	PIWI Expression and Function in Cancer. <i>Frontiers in Genetics</i> , 2012, 3, 204.	1.1	110
398	The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells. <i>Carcinogenesis</i> , 2012, 33, 1871-1881.	1.3	26
399	Cancer therapy with genetically modified T cells for the treatment of melanoma. <i>Journal of Gene Medicine</i> , 2012, 14, 400-404.	1.4	8
400	Expression of cancer testis antigens MAGEA4 and MAGEC1 in oral squamous cell carcinoma. <i>Head and Neck</i> , 2012, 34, 1123-1128.	0.9	22
401	Spontaneous antibody, and CD4 and CD8 T cell responses against MAGEA1b (GAGED2a) in non-small cell lung cancer patients. <i>International Journal of Cancer</i> , 2012, 131, E649-58.	2.3	33
402	Raising the Bar: The Curative Potential of Human Cancer Immunotherapy. <i>Science Translational Medicine</i> , 2012, 4, 127ps8.	5.8	218
403	Cancer testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis. <i>Cancer</i> , 2012, 118, 1845-1855.	2.0	44
404	Adoptive immunotherapy for cancer: harnessing the T cell response. <i>Nature Reviews Immunology</i> , 2012, 12, 269-281.	10.6	1,412
405	Dissecting the First Transcriptional Divergence During Human Embryonic Development. <i>Stem Cell Reviews and Reports</i> , 2012, 8, 150-162.	5.6	73
406	Genetic engineering with T cell receptors. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 756-762.	6.6	24
407	First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. <i>Cancer Science</i> , 2012, 103, 150-153.	1.7	53
408	Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 89-102.	3.3	46
409	Parallel mechanisms of epigenetic reprogramming in the germline. <i>Trends in Genetics</i> , 2012, 28, 164-174.	2.9	163
410	<i>Drosophila</i> cancer models. <i>Developmental Dynamics</i> , 2012, 241, 107-118.	0.8	108

#	ARTICLE	IF	CITATIONS
411	Sequence and expression of the chicken membrane-associated phospholipases A1 alpha (LIPH) and beta (LIPI). <i>Molecular Biology Reports</i> , 2012, 39, 761-769.	1.0	7
412	Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 519-527.	1.2	42
413	Induction of CD8 T cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1 (NY-ESO-1 91-110) peptide. <i>International Journal of Cancer</i> , 2013, 132, 345-354.	2.3	27
414	Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. <i>Cell Communication and Signaling</i> , 2013, 11, 41.	2.7	21
415	Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma. <i>Journal of Translational Medicine</i> , 2013, 11, 123.	1.8	16
416	SPAG9 is overexpressed in human astrocytoma and promotes cell proliferation and invasion. <i>Tumor Biology</i> , 2013, 34, 2849-2855.	0.8	27
417	Cohesin complexes with a potential to link mammalian meiosis to cancer. <i>Cell Regeneration</i> , 2013, 2, 2:4.	1.1	14
418	Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-associated testis (CT-X) antigens. <i>BMC Cancer</i> , 2013, 13, 156.	1.1	15
419	Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 565-574.	1.4	13
420	Elevated expression of cancer/testis antigen FSIP1 in ER-positive breast tumors. <i>Biomarkers in Medicine</i> , 2013, 7, 601-611.	0.6	21
422	The evolution of systemic therapy in sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 211-223.	1.1	23
423	NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches. <i>Cancer Immunology Research</i> , 2013, 1, 296-302.	1.6	15
424	Expression of cancer/testis (CT) antigens in squamous cell carcinoma of the head and neck: Evaluation as markers of squamous dysplasia. <i>Pathology Research and Practice</i> , 2013, 209, 721-726.	1.0	17
425	High-throughput identification of antigen-specific TCRs by TCR gene capture. <i>Nature Medicine</i> , 2013, 19, 1534-1541.	15.2	166
426	Immunotherapy for advanced melanoma: Fulfilling the promise. <i>Cancer Treatment Reviews</i> , 2013, 39, 879-885.	3.4	44
427	Epigenetic Alterations in Oncogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, v-vii.	0.8	10
428	Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. <i>BMC Cancer</i> , 2013, 13, 466.	1.1	32
429	Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 69.	3.5	38

#	ARTICLE	IF	CITATIONS
430	Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. <i>Cancer Cell International</i> , 2013, 13, 92.	1.8	131
431	Evaluation of MAGE-4 expression in hepatocellular carcinoma in Japanese patients. <i>Journal of Surgical Oncology</i> , 2013, 108, 557-562.	0.8	22
432	Adoptive T-cell Therapy. , 2013, , 261-272.		0
433	The expression and clinical significance of melanoma-associated antigen-A1, -A3 and -A11 in glioma. <i>Oncology Letters</i> , 2013, 6, 55-62.	0.8	19
434	Epigenetic Targeting Therapies to Overcome Chemotherapy Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, 285-311.	0.8	23
435	MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 191-195.	2.0	23
436	Germline traits of human hepatoblastoma cells associated with growth and metastasis. <i>Biochemical and Biophysical Research Communications</i> , 2013, 437, 120-126.	1.0	8
437	Regulatory T cells and vasectomy. <i>Journal of Reproductive Immunology</i> , 2013, 100, 66-75.	0.8	28
438	An HLA-modified ovarian cancer cell line induced CTL responses specific to an epitope derived from claudin-1 presented by HLA-A*24:02 molecules. <i>Human Immunology</i> , 2013, 74, 1103-1110.	1.2	6
439	Expression of MAGE-A restricted to testis and ovary or to various cancers in dogs. <i>Veterinary Immunology and Immunopathology</i> , 2013, 153, 26-34.	0.5	6
440	Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern. <i>Medical Oncology</i> , 2013, 30, 368.	1.2	28
441	Epigenetic Regulation of Male Germ Cell Differentiation. <i>Sub-Cellular Biochemistry</i> , 2013, 61, 119-138.	1.0	27
442	<i>Drosophila melanogaster</i> : a model and a tool to investigate malignancy and identify new therapeutics. <i>Nature Reviews Cancer</i> , 2013, 13, 172-183.	12.8	246
443	Translating sperm protein 17 as a target for immunotherapy from the bench to the bedside in the light of cancer complexity. <i>Tissue Antigens</i> , 2013, 81, 116-118.	1.0	1
444	New targets for the immunotherapy of colon cancer—does reactive disease hold the answer?. <i>Cancer Gene Therapy</i> , 2013, 20, 157-168.	2.2	17
445	RNA-based regulation of pluripotency. <i>Trends in Genetics</i> , 2013, 29, 99-107.	2.9	29
446	Molecular and cellular pathogenesis of melanoma initiation and progression. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 4055-4065.	2.4	51
447	Novel dimensions of piRNAs in cancer. <i>Cancer Letters</i> , 2013, 336, 46-52.	3.2	107

#	ARTICLE	IF	CITATIONS
448	EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1211-1222.	2.0	7
449	Scanning of novel cancer/testis proteins by human testis proteomic analysis. <i>Proteomics</i> , 2013, 13, 1200-1210.	1.3	54
450	Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung Cancers. <i>Science Translational Medicine</i> , 2013, 5, 186ra66.	5.8	392
451	MAGEA10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas. <i>International Journal of Cancer</i> , 2013, 132, 2459-2463.	2.3	24
452	The mammalian germline as a pluripotency cycle. <i>Development (Cambridge)</i> , 2013, 140, 2495-2501.	1.2	55
453	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e23803.	2.1	92
454	A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. <i>Cancer Letters</i> , 2013, 328, 160-167.	3.2	37
455	Analysis of compensatory substitution and gene evolution on the MAGEA/CSAG-palindrome of the primate X chromosomes. <i>Computational Biology and Chemistry</i> , 2013, 42, 18-22.	1.1	1
456	Cancer Stem Cells: A Review of Potential Clinical Applications. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1111-1116.	1.2	38
457	Mobilizing and evaluating anticancer T cells: pitfalls and solutions. <i>Expert Review of Vaccines</i> , 2013, 12, 1325-1340.	2.0	5
458	The Histone Demethylase Jarid1b Ensures Faithful Mouse Development by Protecting Developmental Genes from Aberrant H3K4me3. <i>PLoS Genetics</i> , 2013, 9, e1003461.	1.5	114
459	Combined Analysis of Serum Alpha-Fetoprotein and MAGE-A3-Specific Cytotoxic T Lymphocytes in Peripheral Blood for Diagnosis of Hepatocellular Carcinoma. <i>Disease Markers</i> , 2013, 35, 915-923.	0.6	10
460	The Novelty of Human Cancer/Testis Antigen Encoding Genes in Evolution. <i>International Journal of Genomics</i> , 2013, 2013, 1-7.	0.8	25
461	Large, Male Germ Cell-Specific Hypomethylated DNA Domains With Unique Genomic and Epigenomic Features on the Mouse X Chromosome. <i>DNA Research</i> , 2013, 20, 549-565.	1.5	10
462	E2f6-mediated repression of the meiotic <i>Stag3</i> and <i>Smc1²</i> genes during early embryonic development requires Ezh2 and not the de novo methyltransferase Dnmt3b. <i>Epigenetics</i> , 2013, 8, 873-884.	1.3	13
463	Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients. <i>Cancer Immunology Research</i> , 2013, 1, 235-244.	1.6	109
464	CD4+ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg. <i>Cancer Immunology Research</i> , 2013, 1, 303-308.	1.6	21
465	Potential Role of Meiosis Proteins in Melanoma Chromosomal Instability. <i>Journal of Skin Cancer</i> , 2013, 2013, 1-9.	0.5	36

#	ARTICLE	IF	CITATIONS
466	Heterogeneous Expression of CT10, CT45 and GAGE7 Antigens and their Prognostic Significance in Human Breast Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 243-250.	0.6	18
467	Testis specific gene expression drives disease progression and Rituximab resistance in lymphoma. <i>EMBO Molecular Medicine</i> , 2013, 5, 1149-1150.	3.3	0
468	A pharmacologic perspective on newly emerging <sc>T</sc>-cell manipulation technologies. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 173-187.	1.1	5
469	DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene <i>MAGEA11</i>. <i>Epigenetics</i> , 2013, 8, 849-863.	1.3	47
470	A Synthetic Small Molecule for Targeted Transcriptional Activation of Germ Cell Genes in a Human Somatic Cell. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 13410-13413.	7.2	45
471	Characterization of Ewing sarcoma associated cancer/testis antigens. <i>Cancer Biology and Therapy</i> , 2013, 14, 254-261.	1.5	21
472	Trial Watch. <i>Oncolmunology</i> , 2013, 2, e24238.	2.1	58
473	DNA methylation dynamics during the mammalian life cycle. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2013, 368, 20110328.	1.8	262
474	Adoptive T-cell transfer in melanoma. <i>Immunotherapy</i> , 2013, 5, 79-90.	1.0	21
475	FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma. <i>Oncology Reports</i> , 2013, 30, 1275-1284.	1.2	8
476	Promoting effects on the proliferation and metastasis of ACC tumor cell with XAGE-1b overexpression. <i>Oncology Reports</i> , 2013, 30, 2323-2335.	1.2	3
477	Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. <i>Blood</i> , 2013, 122, 348-356.	0.6	61
478	Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. <i>Blood</i> , 2013, 122, 863-871.	0.6	932
479	Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness. <i>Prostate</i> , 2013, 73, 1103-1114.	1.2	18
480	Interaction-based evolution: how natural selection and nonrandom mutation work together. <i>Biology Direct</i> , 2013, 8, 24.	1.9	29
481	MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer. <i>Haematologica</i> , 2013, 98, 316-322.	1.7	7
482	Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring. <i>Biomedical Research</i> , 2013, 34, 41-50.	0.3	4
483	Differential Expression of PRAMEL1, a Cancer/Testis Antigen, during Spermatogenesis in the Mouse. <i>PLoS ONE</i> , 2013, 8, e60611.	1.1	23

#	ARTICLE	IF	CITATIONS
484	The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e67876.	1.1	31
485	Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine. <i>PLoS ONE</i> , 2013, 8, e70522.	1.1	64
486	Synergistic Re-Activation of Epigenetically Silenced Genes by Combinatorial Inhibition of DNMTs and LSD1 in Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e75136.	1.1	33
487	Sperm Associated Antigen 9 Plays an Important Role in Bladder Transitional Cell Carcinoma. <i>PLoS ONE</i> , 2013, 8, e81348.	1.1	32
488	Dendritic Cell-Specific Delivery of Flt3L by Coronavirus Vectors Secures Induction of Therapeutic Antitumor Immunity. <i>PLoS ONE</i> , 2013, 8, e81442.	1.1	7
489	Signal Transduction in Human Cutaneous Melanoma and Target Drugs. <i>Current Cancer Drug Targets</i> , 2013, 13, 843-866.	0.8	56
490	Cancer testis antigen and immunotherapy. <i>ImmunoTargets and Therapy</i> , 2013, 2, 11.	2.7	43
491	Bioinformatics for spermatogenesis: annotation of male reproduction based on proteomics. <i>Asian Journal of Andrology</i> , 2013, 15, 594-602.	0.8	32
492	A Distinct Expression Pattern of Cyclin K in Mammalian Testes Suggests a Functional Role in Spermatogenesis. <i>PLoS ONE</i> , 2014, 9, e101539.	1.1	19
493	STK31/TDRD8, a Germ Cell-Specific Factor, Is Dispensable for Reproduction in Mice. <i>PLoS ONE</i> , 2014, 9, e89471.	1.1	17
494	Differences in Gene Expression between Mouse and Human for Dynamically Regulated Genes in Early Embryo. <i>PLoS ONE</i> , 2014, 9, e102949.	1.1	25
495	A Panel of Cancer Testis Antigens and Clinical Risk Factors to Predict Metastasis in Colorectal Cancer. <i>Journal of Biomarkers</i> , 2014, 2014, 1-8.	1.0	4
496	Clinical Significance of Immunohistochemical Expression of Cancer/Testis Tumor-associated Antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in Patients with Non-small Cell Lung Cancer. <i>Tumori</i> , 2014, 100, 60-68.	0.6	19
497	Attenuated <i>Listeria monocytogenes</i> : a powerful and versatile vector for the future of tumor immunotherapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2014, 4, 51.	1.8	112
498	Dnmt3b Prefers Germ Line Genes and Centromeric Regions: Lessons from the ICF Syndrome and Cancer and Implications for Diseases. <i>Biology</i> , 2014, 3, 578-605.	1.3	30
499	A novel cohort of cancer-testis biomarker genes revealed through meta-analysis of clinical data sets.. <i>Oncoscience</i> , 2014, 1, 349-359.	0.9	24
500	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e28185.	2.1	36
501	Genomic screening of testicular germ cell tumors from monozygotic twins. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 181.	1.2	7

#	ARTICLE	IF	CITATIONS
502	Cancer testis antigen expression in testicular germ cell tumorigenesis. <i>Modern Pathology</i> , 2014, 27, 899-905.	2.9	22
503	Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer. <i>Oncogene</i> , 2014, 33, 4579-4588.	2.6	35
504	Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells. <i>Frontiers in Oncology</i> , 2014, 4, 367.	1.3	29
505	<i>Drosophila</i> neuroblasts as a new model for the study of stem cell self-renewal and tumour formation. <i>Bioscience Reports</i> , 2014, 34, .	1.1	17
506	CD8+ TIL Recruitment May Revert the Association of MAGE A3 with Aggressive Features in Thyroid Tumors. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	0.9	6
507	Evolving Strategies for Cancer and Autoimmunity: Back to the Future. <i>Frontiers in Immunology</i> , 2014, 5, 154.	2.2	4
508	Gender-Associated Genomic Differences in Colorectal Cancer: Clinical Insight from Feminization of Male Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2014, 15, 17344-17365.	1.8	16
509	Overexpression of Testes-Specific Protease 50 (TSP50) Predicts Poor Prognosis in Patients with Gastric Cancer. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-7.	0.7	14
510	Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens. <i>Frontiers in Immunology</i> , 2014, 5, 191.	2.2	71
512	Vaccines and early breast cancer. <i>Cell Cycle</i> , 2014, 13, 1359-1359.	1.3	1
513	Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. <i>Modern Pathology</i> , 2014, 27, 1238-1245.	2.9	55
514	Effects of Four Chemotherapeutic Agents, Bleomycin, Etoposide, Cisplatin, and Cyclophosphamide, on DNA Damage and Telomeres in a Mouse Spermatogonial Cell Line1. <i>Biology of Reproduction</i> , 2014, 90, 72.	1.2	63
515	Simultaneous cytoplasmic and nuclear protein expression of melanoma antigenâ€A family and NYâ€ESOâ€ cancerâ€testis antigens represents an independent marker for poor survival in head and neck cancer. <i>International Journal of Cancer</i> , 2014, 135, 1142-1152.	2.3	46
516	Melanoma-associated antigen genes: a new trend to predict the prognosis of breast cancer patients. <i>Medical Oncology</i> , 2014, 31, 285.	1.2	12
517	The RNA/DNAâ€binding protein PSF relocates to cell membrane and contributes cells' sensitivity to antitumor drug, doxorubicin. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2014, 85, 231-241.	1.1	10
518	Advances in Tumor Immunology and Immunotherapy. , 2014, , .		2
519	Metaâ€analysis of expression of l(3)mbt tumorâ€associated germline genes supports the model that a somaâ€toâ€germline transition is a hallmark of human cancers. <i>International Journal of Cancer</i> , 2014, 134, 2359-2365.	2.3	28
520	Sperm Protein17 is an Oncofetal Antigen: A Lesson From a Murine Model. <i>International Reviews of Immunology</i> , 2014, 33, 367-374.	1.5	11

#	ARTICLE	IF	CITATIONS
521	<i>In vitro</i> and <i>ex vivo</i> evaluation of a multi-epitope heparinase vaccine for various malignancies. <i>Cancer Science</i> , 2014, 105, 9-17.	1.7	6
522	Tumor Subtype-Specific Cancer-Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers. <i>Cancer Immunology Research</i> , 2014, 2, 371-379.	1.6	90
523	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolmunology</i> , 2014, 3, e963424.	2.1	62
524	Expression of MAGE-A3/6 in Primary Breast Cancer is Associated With Hormone Receptor Negative Status, High Histologic Grade, and Poor Survival. <i>Journal of Immunotherapy</i> , 2014, 37, 73-76.	1.2	35
525	CancerEST: a web-based tool for automatic meta-analysis of public EST data. <i>Database: the Journal of Biological Databases and Curation</i> , 2014, 2014, bau024-bau024.	1.4	5
526	Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody. <i>Clinical Cancer Research</i> , 2014, 20, 5052-5063.	3.2	19
527	Senescent Remodeling of the Innate and Adaptive Immune System in the Elderly Men with Prostate Cancer. <i>Current Gerontology and Geriatrics Research</i> , 2014, 2014, 1-11.	1.6	18
528	XAGE-1b expression is associated with the diagnosis and early recurrence of hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2014, 2, 1155-1159.	0.4	7
529	Sarcoma Immunotherapy: Past Approaches and Future Directions. <i>Sarcoma</i> , 2014, 2014, 1-13.	0.7	43
530	Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion <i>in vitro</i> . <i>Molecular Carcinogenesis</i> , 2014, 53, 970-978.	1.3	23
531	A personalized view on cancer immunotherapy. <i>Cancer Letters</i> , 2014, 352, 113-125.	3.2	63
532	Association of polymorphisms at <i>HORMAD2</i> and prognosis in advanced non-small-cell lung cancer patients. <i>Cancer Epidemiology</i> , 2014, 38, 414-418.	0.8	5
533	Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells. <i>Clinical Oral Investigations</i> , 2014, 18, 189-197.	1.4	21
534	Expressions of MAGE-A9 and MAGE-A11 in Breast Cancer and their Expression Mechanism. <i>Archives of Medical Research</i> , 2014, 45, 44-51.	1.5	33
535	Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment. <i>Cancer Drug Discovery and Development</i> , 2014, , 553-568.	0.2	0
536	Cancer/Testis Antigen PAGE4, a Regulator of c-Jun Transactivation, Is Phosphorylated by Homeodomain-Interacting Protein Kinase 1, a Component of the Stress-Response Pathway. <i>Biochemistry</i> , 2014, 53, 1670-1679.	1.2	42
537	Novel regulators of spermatogenesis. <i>Seminars in Cell and Developmental Biology</i> , 2014, 29, 31-42.	2.3	38
538	NY-ESO-1 expression is tightly linked to <i>TPRSS2-ERG</i> fusion in prostate cancer. <i>Prostate</i> , 2014, 74, 1012-1022.	1.2	10

#	ARTICLE	IF	CITATIONS
539	Cancerâ€™Testis Antigen Expression in Digestive Tract Carcinomas: Frequent Expression in Esophageal Squamous Cell Carcinoma and Its Precursor Lesions. <i>Cancer Immunology Research</i> , 2014, 2, 480-486.	1.6	31
540	Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens. <i>International Journal of Cancer</i> , 2014, 135, 1842-1851.	2.3	20
541	Interaction of Immune and Cancer Cells. , 2014, , .		0
542	Cause and Consequence of Cancer/Testis Antigen Activation in Cancer. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 251-272.	4.2	201
543	Protein Deimination in Human Health and Disease. , 2014, , .		10
544	Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 24-37.	12.5	380
545	Sex disparities in melanoma outcomes: The role of biology. <i>Archives of Biochemistry and Biophysics</i> , 2014, 563, 42-50.	1.4	53
546	MAGE proteins regulate KRAB zinc finger transcription factors and KAP1 E3 ligase activity. <i>Archives of Biochemistry and Biophysics</i> , 2014, 563, 136-144.	1.4	14
547	RNA interference against cancer/testis genes identifies dual specificity phosphatase 21 as a potential therapeutic target in human hepatocellular carcinoma. <i>Hepatology</i> , 2014, 59, 518-530.	3.6	18
548	The SCF/c-KIT system in the male: Survival strategies in fertility and cancer. <i>Molecular Reproduction and Development</i> , 2014, 81, 1064-1079.	1.0	31
549	<scp>SSX2</scp>â€™4 expression in earlyâ€™stage nonâ€™small cell lung cancer. <i>Tissue Antigens</i> , 2014, 83, 344-349.	1.0	16
550	OVA66 increases cell growth, invasion and survival via regulation of IGF-1Râ€™MAPK signaling in human cancer cells. <i>Carcinogenesis</i> , 2014, 35, 1573-1581.	1.3	19
551	New genes contribute to genetic and phenotypic novelties in human evolution. <i>Current Opinion in Genetics and Development</i> , 2014, 29, 90-96.	1.5	56
552	MHC-Restricted Phosphopeptides from Insulin Receptor Substrate-2 and CDC25b Offer Broad-Based Immunotherapeutic Agents for Cancer. <i>Cancer Research</i> , 2014, 74, 6784-6795.	0.4	28
553	Cancer/testis antigens: A prospective reagent as diagnostic and immunotherapeutic targets for squamous cell carcinoma of the head and neck. <i>Japanese Dental Science Review</i> , 2014, 50, 91-99.	2.0	1
554	Survey of autoantibody responses against tumor-associated antigens in thyroid cancer. <i>Cancer Biomarkers</i> , 2014, 14, 361-369.	0.8	19
555	Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 331-343.	3.2	55
556	A novel cancer-germline transcript carrying pro-metastatic miR-105 and<i>TET</i>-targeting miR-767 induced by DNA hypomethylation in tumors. <i>Epigenetics</i> , 2014, 9, 1163-1171.	1.3	56

#	ARTICLE	IF	CITATIONS
557	Very small embryonic-like stem cells as a novel developmental concept and the hierarchy of the stem cell compartment. <i>Advances in Medical Sciences</i> , 2014, 59, 273-280.	0.9	42
558	Seminal plasma as a diagnostic fluid for male reproductive system disorders. <i>Nature Reviews Urology</i> , 2014, 11, 278-288.	1.9	159
559	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e28344.	2.1	31
560	Expression of the erythropoietin receptor by germline-derived cells - further support for a potential developmental link between the germline and hematopoiesis. <i>Journal of Ovarian Research</i> , 2014, 7, 66.	1.3	31
561	The Potential for Immunogenicity of Autologous Induced Pluripotent Stem Cell-derived Therapies. <i>Journal of Biological Chemistry</i> , 2014, 289, 4571-4577.	1.6	48
562	Lyar, a cell growth-regulating zinc finger protein, was identified to be associated with cytoplasmic ribosomes in male germ and cancer cells. <i>Molecular and Cellular Biochemistry</i> , 2014, 395, 221-229.	1.4	16
563	Engineered T cells for cancer therapy. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 969-975.	2.0	105
564	Loss of nuclear prothymosin- α expression is associated with disease progression in human superficial bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 717-724.	1.4	9
565	A Search for Novel Cancer/Testis Antigens in Lung Cancer Identifies VCX/Y Genes, Expanding the Repertoire of Potential Immunotherapeutic Targets. <i>Cancer Research</i> , 2014, 74, 4694-4705.	0.4	40
566	Evolutionary Origin and Human-Specific Expansion of a Cancer/Testis Antigen Gene Family. <i>Molecular Biology and Evolution</i> , 2014, 31, 2365-2375.	3.5	15
567	Tumor antigen discovery through translation of the cancer genome. <i>Immunologic Research</i> , 2014, 58, 292-299.	1.3	13
568	Pathway landscapes and epigenetic regulation in breast cancer and melanoma cell lines. <i>Theoretical Biology and Medical Modelling</i> , 2014, 11, S8.	2.1	9
569	A high resolution map of mammalian X chromosome fragile regions assessed by large-scale comparative genomics. <i>Mammalian Genome</i> , 2014, 25, 618-635.	1.0	5
570	Immunotherapy Strategies in Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 927-943.	0.9	12
571	High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. <i>Vaccine</i> , 2014, 32, 5901-5907.	1.7	54
572	Identification and analysis of CD133+ melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response. <i>Cancer Letters</i> , 2014, 343, 123-133.	3.2	59
573	Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells. <i>Immunology Letters</i> , 2014, 158, 175-182.	1.1	9
574	Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1307-1312.	0.5	11

#	ARTICLE	IF	CITATIONS
575	Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. <i>Immunology Letters</i> , 2014, 161, 20-30.	1.1	24
576	Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas. <i>Acta Histochemica</i> , 2014, 116, 740-746.	0.9	7
577	The Stress-response protein prostate-associated gene 4, interacts with c-Jun and potentiates its transactivation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 154-163.	1.8	35
578	Generation and Characterization of an Immortalized Human Mesenchymal Stromal Cell Line. <i>Stem Cells and Development</i> , 2014, 23, 2377-2389.	1.1	38
579	The utility of immunostaining for <sc>NUT</sc>, <sc>GAGE</sc>7 and <sc>NY</sc>-<sc>ESO</sc>1 in the diagnosis of spermatocytic seminoma. <i>Histopathology</i> , 2014, 65, 35-44.	1.6	26
580	SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro. <i>Oncology Reports</i> , 2014, 32, 2533-2540.	1.2	14
581	Proteomic analysis reveals that MAEL, a component of nuage, interacts with stress granule proteins in cancer cells. <i>Oncology Reports</i> , 2014, 31, 342-350.	1.2	22
582	Immunotherapy for stage I-III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. <i>The Cochrane Library</i> , 2014, , .	1.5	1
583	The development of a malignant tumor is due to a desperate asexual self-cloning process in which cancer stem cells develop the ability to mimic the genetic program of germline cells. <i>Intrinsically Disordered Proteins</i> , 2014, 2, e29997.	1.9	29
584	Composite peptide-based vaccines for cancer immunotherapy (Review). <i>International Journal of Molecular Medicine</i> , 2015, 35, 17-23.	1.8	16
585	Targeted Knockdown of the Kinetochore Protein D40/Knl-1 Inhibits Human Cancer in a p53 Status-Independent Manner. <i>Scientific Reports</i> , 2015, 5, 13676.	1.6	16
586	Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer. <i>Oncology Letters</i> , 2015, 10, 1211-1217.	0.8	7
587	Elevated Expression of the Testis-specific Gene <i>WBP2NL</i> in Breast Cancer. <i>Biomarkers in Cancer</i> , 2015, 7, BIC.S19079.	3.6	31
588	Activation of the germ-cell potential of human bone marrow-derived cells by a chemical carcinogen. <i>Scientific Reports</i> , 2015, 4, 5564.	1.6	10
589	piRNA involvement in genome stability and human cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 38.	6.9	112
590	A gene expression signature identifying transient DNMT1 depletion as a causal factor of cancer-germline gene activation in melanoma. <i>Clinical Epigenetics</i> , 2015, 7, 114.	1.8	17
591	The effects of chemotherapy with bleomycin, etoposide, and cisâ€platinum on telomeres in rat male germ cells. <i>Andrology</i> , 2015, 3, 1104-1112.	1.9	16
592	Tumor neoantigens: building a framework for personalized cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2015, 125, 3413-3421.	3.9	502

#	ARTICLE	IF	CITATIONS
593	The Use of MAGE C1 and Flow Cytometry to Determine the Malignant Cell Type in Multiple Myeloma. PLoS ONE, 2015, 10, e0120734.	1.1	14
594	Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PLoS ONE, 2015, 10, e0140483.	1.1	13
595	MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4. PLoS ONE, 2015, 10, e0127713.	1.1	36
596	Immunotherapy for Bone and Soft Tissue Sarcomas. BioMed Research International, 2015, 2015, 1-11.	0.9	16
597	Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma. BioMed Research International, 2015, 2015, 1-5.	0.9	6
598	Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma. Journal of Immunology Research, 2015, 2015, 1-8.	0.9	14
599	TRIM proteins legitimately enter the MAGEic RING. Cell Cycle, 2015, 14, 1134-1135.	1.3	2
600	Transcriptome analysis of the cancer/testis genes, DAZ1, AURKC, and TEX101, in breast tumors and six breast cancer cell lines. Tumor Biology, 2015, 36, 8201-8206.	0.8	18
601	Functional Module Analysis for Gene Coexpression Networks with Network Integration. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2015, 12, 1146-1160.	1.9	26
602	BAP31, a promising target for the immunotherapy of malignant melanomas. Journal of Experimental and Clinical Cancer Research, 2015, 34, 36.	3.5	22
603	Maternal-fetal conflict, genomic imprinting and mammalian vulnerabilities to cancer. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140178.	1.8	36
604	A Forward Genetic Screen for Suppressors of Somatic P Granules in Caenorhabditis elegans. G3: Genes, Genomes, Genetics, 2015, 5, 2209-2215.	0.8	1
605	Genome management and mismanagement—cell-level opportunities and challenges of whole-genome duplication. Genes and Development, 2015, 29, 2405-2419.	2.7	33
606	miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer. Translational Oncology, 2015, 8, 85-96.	1.7	15
607	MAGE-A expression clusters and antineoplastic treatment in head and neck cancer. International Journal of Molecular Medicine, 2015, 35, 1675-1682.	1.8	8
608	Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase. Cell, 2015, 160, 715-728.	13.5	285
609	Trial Watch: Peptide-based anticancer vaccines. OncoImmunology, 2015, 4, e974411.	2.1	97
610	Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. Molecular Oncology, 2015, 9, 437-449.	2.1	33

#	ARTICLE	IF	CITATIONS
611	Decitabine: a promising epi-immunotherapeutic agent in solid tumors. Expert Review of Clinical Immunology, 2015, 11, 363-375.	1.3	31
612	Sperm protein 17 and AKAP-associated sperm protein cancer/testis antigens are expressed in ciliated hepatic foregut cysts. Histopathology, 2015, 67, 398-403.	1.6	4
613	Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects. Archives of Pharmacal Research, 2015, 38, 1415-1433.	2.7	14
614	Evaluation of melanoma antigen (MAGE) gene expression in human cancers using The Cancer Genome Atlas. Cancer Genetics, 2015, 208, 25-34.	0.2	15
615	MILI, a PIWI family protein, inhibits melanoma cell migration through methylation of LINE1. Biochemical and Biophysical Research Communications, 2015, 457, 514-519.	1.0	7
616	The melanoma-associated antigen 1 (MAGEA1) protein stimulates the E3 ubiquitin-ligase activity of TRIM31 within a TRIM31-MAGEA1-NSE4 complex. Cell Cycle, 2015, 14, 920-930.	1.3	45
617	Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity. Cell, 2015, 160, 48-61.	13.5	2,948
618	XAGE-1b Cancer/Testis Antigen Is a Potential Target for Immunotherapy in Prostate Cancer. Urologia Internationalis, 2015, 94, 354-362.	0.6	1
619	Epigenetics of Melanoma. , 2015, , 339-361.		1
620	SCML2 Establishes the Male Germline Epigenome through Regulation of Histone H2A Ubiquitination. Developmental Cell, 2015, 32, 574-588.	3.1	109
621	Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents. Frontiers in Immunology, 2015, 6, 29.	2.2	139
622	Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. Seminars in Oncology, 2015, 42, 626-639.	0.8	76
623	Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. Frontiers in Immunology, 2015, 6, 67.	2.2	122
624	Polycomb Protein SCML2 Associates with USP7 and Counteracts Histone H2A Ubiquitination in the XY Chromatin during Male Meiosis. PLoS Genetics, 2015, 11, e1004954.	1.5	58
625	DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Epigenetics, 2015, 10, 736-748.	1.3	52
626	Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer. Scientific Reports, 2015, 5, 12104.	1.6	41
627	Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy. Blood, 2015, 125, 261-272.	0.6	12
628	Targeting Tumor Initiating Cells through Inhibition of Cancer Testis Antigens and Notch Signaling: A Hypothesis. International Reviews of Immunology, 2015, 34, 188-199.	1.5	3

#	ARTICLE	IF	CITATIONS
629	Cancer-Testis Antigens and Immunotherapy in the Light of Cancer Complexity. <i>International Reviews of Immunology</i> , 2015, 34, 143-153.	1.5	27
630	Vaccine therapy in NSCLC: a review. <i>Lung Cancer Management</i> , 2015, 4, 31-41.	1.5	1
631	From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. <i>Experimental Biology and Medicine</i> , 2015, 240, 1087-1098.	1.1	52
632	New York esophageal squamous cell carcinoma-1 and cancer immunotherapy. <i>Immunotherapy</i> , 2015, 7, 411-439.	1.0	25
633	Functional significance of the sex chromosomes during spermatogenesis. <i>Reproduction</i> , 2015, 149, R265-R277.	1.1	17
634	Cancer/Testis Antigen PASD1 Silences the Circadian Clock. <i>Molecular Cell</i> , 2015, 58, 743-754.	4.5	51
635	Overexpression of SPAG9 in human gastric cancer is correlated with poor prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 525-533.	1.4	13
636	Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation. <i>BMC Cancer</i> , 2015, 15, 816.	1.1	86
637	Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1109-1121.	2.0	11
638	In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. <i>Cell Death and Disease</i> , 2015, 6, e1711-e1711.	2.7	67
639	Overexpression of melanoma-associated antigen D4 is an independent prognostic factor in squamous cell carcinoma of the esophagus. <i>Ecological Management and Restoration</i> , 2015, 28, 188-195.	0.2	15
640	Luzp4 defines a new mRNA export pathway in cancer cells. <i>Nucleic Acids Research</i> , 2015, 43, 2353-2366.	6.5	56
641	Tissue-Based Proteogenomics Reveals that Human Testis Endows Plentiful Missing Proteins. <i>Journal of Proteome Research</i> , 2015, 14, 3583-3594.	1.8	45
642	The MAGE protein family and cancer. <i>Current Opinion in Cell Biology</i> , 2015, 37, 1-8.	2.6	184
643	Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions. <i>Genome Biology</i> , 2015, 16, 161.	3.8	83
644	Phosphorylation-induced Conformational Ensemble Switching in an Intrinsically Disordered Cancer/Testis Antigen. <i>Journal of Biological Chemistry</i> , 2015, 290, 25090-25102.	1.6	55
645	Comprehensive functional characterization of cancer testis antigens defines obligate participation in multiple hallmarks of cancer. <i>Nature Communications</i> , 2015, 6, 8840.	5.8	94
646	Active Immunotherapy of Cancer. <i>Immunological Investigations</i> , 2015, 44, 817-836.	1.0	41

#	ARTICLE	IF	CITATIONS
647	Chromosomal aberrations of cancerâ€“testis antigens in myeloma patients. <i>Hematological Oncology</i> , 2015, 33, 159-163.	0.8	1
648	Identification of miR-145 targets through an integrated omics analysis. <i>Molecular BioSystems</i> , 2015, 11, 197-207.	2.9	21
649	T cellâ€“based targeted immunotherapies for patients with multiple myeloma. <i>International Journal of Cancer</i> , 2015, 136, 1751-1768.	2.3	10
650	MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition. <i>Neoplasma</i> , 2016, 63, 44-56.	0.7	14
651	SPAG9 is involved in hepatocarcinoma cell migration and invasion via modulation of ELK1 expression. <i>OncoTargets and Therapy</i> , 2016, 9, 1067.	1.0	25
652	Expression of Cancer Testis Antigens in Colorectal Cancer: New Prognostic and Therapeutic Implications. <i>Disease Markers</i> , 2016, 2016, 1-9.	0.6	21
653	T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2016, 7, 353.	2.2	77
654	Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability. <i>International Journal of Molecular Sciences</i> , 2016, 17, 890.	1.8	37
655	Immunogenic FEAT protein circulates in the bloodstream of cancer patients. <i>Journal of Translational Medicine</i> , 2016, 14, 275.	1.8	8
656	CD4 T Cells in Antitumor Immunity. , 2016, , 441-450.		2
657	Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort. <i>Oncotarget</i> , 2016, 7, 13945-13964.	0.8	34
658	Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. <i>Oncotarget</i> , 2016, 7, 16420-16432.	0.8	42
659	The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker. <i>Prostate</i> , 2016, 76, 1271-1284.	1.2	26
660	MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases. <i>Journal of Immunotherapy</i> , 2016, 39, 181-187.	1.2	54
661	A genomic region transcribed into a long noncoding RNA interacts with the <i>Prss42</i> promoter in spermatocytes during mouse spermatogenesis, and its flanking sequences can function as enhancers. <i>Molecular Reproduction and Development</i> , 2016, 83, 541-557.	1.0	29
662	The fission yeast MTREC and EJC orthologs ensure the maturation of meiotic transcripts during meiosis. <i>Rna</i> , 2016, 22, 1349-1359.	1.6	5
663	An aptamer targeting shared tumorâ€“specific peptide antigen of MAGEâ€“A3 in multiple cancers. <i>International Journal of Cancer</i> , 2016, 138, 918-926.	2.3	25
664	Expression of evolutionarily novel genes in tumors. <i>Infectious Agents and Cancer</i> , 2016, 11, 34.	1.2	18

#	ARTICLE	IF	CITATIONS
665	Expression of MAGE-A1-A12 subgroups in the invasive tumor front and tumor center in oral squamous cell carcinoma. <i>Oncology Reports</i> , 2016, 35, 1979-1986.	1.2	14
666	Biochemistry of Oxidative Stress. , 2016, , .		5
667	Cancer cells activate damage-tolerant and error-prone DNA synthesis. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1225547.	0.3	0
669	Biochemical and proteomic characterization of retrovirus Gag based microparticles carrying melanoma antigens. <i>Scientific Reports</i> , 2016, 6, 29425.	1.6	14
670	Comment on "Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area". <i>British Journal of Cancer</i> , 2016, 114, e1-e1.	2.9	0
671	A neomorphic cancer cell-specific role of MAGE-A4 in trans-lesion synthesis. <i>Nature Communications</i> , 2016, 7, 12105.	5.8	52
672	Expression profile of SPACA5/Spaca5 in spermatogenesis and transitional cell carcinoma of the bladder. <i>Oncology Letters</i> , 2016, 12, 3731-3738.	0.8	8
673	Pathological trans-lesion synthesis in cancer. <i>Cell Cycle</i> , 2016, 15, 3005-3006.	1.3	8
674	MAGE-A1 expression in patients with head and neck squamous cell carcinoma: impact on clinical patterns and oncologic outcomes. <i>International Journal of Clinical Oncology</i> , 2016, 21, 875-882.	1.0	10
675	An unregulated regulator: Vasa expression in the development of somatic cells and in tumorigenesis. <i>Developmental Biology</i> , 2016, 415, 24-32.	0.9	26
676	SPAG9 controls the cell motility, invasion and angiogenesis of human osteosarcoma cells. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 637-644.	0.8	8
677	The role of neoantigens in response to immune checkpoint blockade. <i>International Immunology</i> , 2016, 28, 411-419.	1.8	148
678	Lentivirus-mediated knockdown of TSP50 suppresses the growth of non-small cell lung cancer cells via G0/G1 phase arrest. <i>Oncology Reports</i> , 2016, 35, 3409-3418.	1.2	11
679	Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells. <i>BMC Cancer</i> , 2016, 16, 134.	1.1	27
680	Role of L1CAM in the Regulation of the Canonical Wnt Pathway and Class I MAGE Genes. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 160, 807-810.	0.3	19
681	Role of Immunity in Pathogenesis and Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2016, 34, 429-437.	0.8	21
682	Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers. <i>Immunological Investigations</i> , 2016, 45, 619-640.	1.0	143
683	A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility. <i>Experimental and Molecular Medicine</i> , 2016, 48, e246-e246.	3.2	9

#	ARTICLE	IF	CITATIONS
684	Identification of a TSPY co-expression network associated with DNA hypomethylation and tumor gene expression in somatic cancers. <i>Journal of Genetics and Genomics</i> , 2016, 43, 577-585.	1.7	8
685	SPAG9 is overexpressed in osteosarcoma, and regulates cell proliferation and invasion through regulation of JunD. <i>Oncology Letters</i> , 2016, 12, 2674-2679.	0.8	6
686	<scp>FATE</scp> 1 antagonizes calcium–and drug–induced apoptosis by uncoupling <scp>ER</scp> and mitochondria. <i>EMBO Reports</i> , 2016, 17, 1264-1280.	2.0	102
688	Mechanisms of immune evasion and current status of checkpoint inhibitors in non–small cell lung cancer. <i>Cancer Medicine</i> , 2016, 5, 2567-2578.	1.3	56
689	Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor growth of triple-negative breast cancer cells. <i>Tumor Biology</i> , 2016, 37, 13101-13110.	0.8	19
690	Oncogenic transformation of <i>Drosophila</i> somatic cells induces a functional piRNA pathway. <i>Genes and Development</i> , 2016, 30, 1623-1635.	2.7	33
691	ER-mitochondria contacts find their FATE. <i>Cell Cycle</i> , 2016, 15, 3159-3160.	1.3	2
692	Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer?. <i>Clinical and Translational Medicine</i> , 2016, 5, 28.	1.7	23
693	Open questions in the study of de novo genes: what, how and why. <i>Nature Reviews Genetics</i> , 2016, 17, 567-578.	7.7	179
694	Immunotherapy for oesophagogastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1197-1207.	1.4	10
695	Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer. <i>Scientific Reports</i> , 2016, 6, 33121.	1.6	28
696	Specific autoantigens identified by sera obtained from mice that are immunized with testicular germ cells alone. <i>Scientific Reports</i> , 2016, 6, 35599.	1.6	13
697	Expression and prognostic significance of the autoimmune regulator gene in breast cancer cells. <i>Cell Cycle</i> , 2016, 15, 3220-3229.	1.3	16
698	Expression of MAGE-A1, -A9, -A11 in laryngeal squamous cell carcinoma and their prognostic significance: a retrospective clinical study. <i>Acta Oto-Laryngologica</i> , 2016, 136, 506-513.	0.3	18
699	Isolation and Characterization of an HLA-DPB1*04:01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. <i>Journal of Immunotherapy</i> , 2016, 39, 191-201.	1.2	27
700	Landscape of tumor-infiltrating T cell repertoire of human cancers. <i>Nature Genetics</i> , 2016, 48, 725-732.	9.4	288
701	Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16 oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer. <i>Virology Journal</i> , 2016, 13, 60.	1.4	26
702	Production of antigen-specific human IgGs by in vitro immunization. <i>BMC Biotechnology</i> , 2016, 16, 22.	1.7	2

#	ARTICLE	IF	CITATIONS
703	Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. <i>Nature Communications</i> , 2016, 7, 10499.	5.8	124
704	Cancer/testis antigen NY-SAR-35 enhances cell proliferation, migration, and invasion. <i>International Journal of Oncology</i> , 2016, 48, 569-576.	1.4	7
705	Regulation of blood–testis barrier by actin binding proteins and protein kinases. <i>Reproduction</i> , 2016, 151, R29-R41.	1.1	44
706	Antigen Selection for Enhanced Affinity T-Cell Receptor–Based Cancer Therapies. <i>Journal of Biomolecular Screening</i> , 2016, 21, 769-785.	2.6	12
707	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Advances in Immunology</i> , 2016, 130, 25-74.	1.1	181
708	Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer. <i>Cellular Oncology (Dordrecht)</i> , 2016, 39, 175-186.	2.1	22
709	PASD1 promotes STAT3 activity and tumor growth by inhibiting TC45-mediated dephosphorylation of STAT3 in the nucleus. <i>Journal of Molecular Cell Biology</i> , 2016, 8, 221-231.	1.5	13
710	Autoantibody Production in Cancer—The Humoral Immune Response toward Autologous Antigens in Cancer Patients. <i>Autoimmunity Reviews</i> , 2016, 15, 477-483.	2.5	196
711	Peptide Vaccine. , 2016, , 135-142.		0
712	Testis expressed 19 is a novel cancer-testis antigen expressed in bladder cancer. <i>Tumor Biology</i> , 2016, 37, 7757-7765.	0.8	14
713	Enhancer of Rudimentary Cooperates with Conserved RNA-Processing Factors to Promote Meiotic mRNA Decay and Facultative Heterochromatin Assembly. <i>Molecular Cell</i> , 2016, 61, 747-759.	4.5	79
714	Aberrant demethylation and expression of MAGEB2 in a subset of malignant peripheral nerve sheath tumors from neurofibromatosis type 1. <i>Journal of Dermatological Science</i> , 2016, 81, 118-123.	1.0	7
715	The expression of MAGE-C1 and MAGE-C2 in breast cancer and their clinical significance. <i>American Journal of Surgery</i> , 2016, 211, 142-151.	0.9	17
716	Personalized approaches to active immunotherapy in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 72-82.	3.3	41
717	Personalized cancer immunotherapy using Systems Medicine approaches. <i>Briefings in Bioinformatics</i> , 2016, 17, 453-467.	3.2	23
718	Elements of cancer immunity and the cancer–immune set point. <i>Nature</i> , 2017, 541, 321-330.	13.7	3,558
719	MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray. <i>Journal of Clinical Pathology</i> , 2017, 70, 533-540.	1.0	24
720	A cancer/testis antigen, NY-SAR-35, induces EpCAM, CD44, and CD133, and activates ERK in HEK293 cells. <i>Biochemical and Biophysical Research Communications</i> , 2017, 484, 298-303.	1.0	4

#	ARTICLE	IF	CITATIONS
721	Lack of XAGEâ€b and NYâ€ESOâ€1 in metastatic lymph nodes may predict the potential survival of stage III melanoma patients. <i>Journal of Dermatology</i> , 2017, 44, 671-680.	0.6	8
722	Targeting neoantigens to augment antitumour immunity. <i>Nature Reviews Cancer</i> , 2017, 17, 209-222.	12.8	724
723	Roles of cancer/testis antigens (CTAs) in breast cancer. <i>Cancer Letters</i> , 2017, 399, 64-73.	3.2	33
724	Marked for death: targeting epigenetic changes in cancer. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 241-263.	21.5	244
725	Untimely expression of gametogenic genes in vegetative cells causes uniparental disomy. <i>Nature</i> , 2017, 543, 126-130.	13.7	32
726	MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation. <i>Oncogenesis</i> , 2017, 6, e312-e312.	2.1	91
727	Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors. <i>Gynecologic Oncology</i> , 2017, 145, 413-419.	0.6	19
728	SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. <i>Molecular Cancer</i> , 2017, 16, 1.	7.9	196
729	A sensitive and disposable indium tin oxide based electrochemical immunosensor for label-free detection of MAGE-1. <i>Talanta</i> , 2017, 169, 163-169.	2.9	19
730	Expression of cancer/testis antigens in salivary gland carcinomas with reference to <scp>MAGE</scp>â€A and <scp>NY</scp>â€<scp>ESO</scp>â€1 expression in adenoid cystic carcinoma. <i>Histopathology</i> , 2017, 71, 305-315.	1.6	11
731	Block spectral clustering for multiple graphs with inter-relation. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2017, 6, 1.	1.2	5
732	Human germ/stem cell-specific gene TEX19 influences cancer cell proliferation and cancer prognosis. <i>Molecular Cancer</i> , 2017, 16, 84.	7.9	20
733	Trends in Scientific Discovery. , 2017, , 31-64.		0
734	Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831769913.	0.8	11
737	Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells. <i>Cancer Immunology Research</i> , 2017, 5, 630-641.	1.6	50
738	Expression of novel cancer/testis antigen TMEM31 increases during metastatic melanoma progression. <i>Oncology Letters</i> , 2017, 13, 2269-2273.	0.8	8
739	Promising immunotherapies for esophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 723-733.	1.4	25
740	Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes. <i>Cancer Letters</i> , 2017, 396, 130-137.	3.2	158

#	ARTICLE	IF	CITATIONS
741	Expression of lactate dehydrogenase C correlates with poor prognosis in renal cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831769596.	0.8	27
742	A novel testis-specific protein, PRAMEY, is involved in spermatogenesis in cattle. <i>Reproduction</i> , 2017, 153, 847-863.	1.1	13
743	Effect of cancer/testis antigen NY-SAR-35 on the proliferation, migration and invasion of cancer cells. <i>Oncology Letters</i> , 2017, 13, 784-790.	0.8	4
744	Prespermatogenesis and early spermatogenesis in frogs. <i>Zoology</i> , 2017, 122, 63-79.	0.6	15
745	Ex Vivo Engineering of the Tumor Microenvironment. <i>Cancer Drug Discovery and Development</i> , 2017, , .	0.2	4
746	The Importance of Circulating Tumor Cells and Tumor Models in Future of Cancer Therapy. <i>Cancer Drug Discovery and Development</i> , 2017, , 121-135.	0.2	0
747	Meiosis-like Functions in Oncogenesis: A New View of Cancer. <i>Cancer Research</i> , 2017, 77, 5712-5716.	0.4	53
748	Sex comb on midleg like-2 is a novel specific marker for the diagnosis of gastroenteropancreatic neuroendocrine tumors. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 1749-1755.	0.8	2
749	An <i>in vivo</i> genetic screen in <i>Drosophila</i> identifies the orthologue of human cancer/testis gene <i>SPO11</i> among a network of targets to inhibit lethal(3) malignant brain tumour growth. <i>Open Biology</i> , 2017, 7, 170156.	1.5	12
750	Nanomaterials for cancer immunotherapy. <i>Biomaterials</i> , 2017, 148, 16-30.	5.7	226
751	A novel electrochemical immunosensor based on ITO modified by carboxyl-ended silane agent for ultrasensitive detection of MAGE-1 in human serum. <i>Analytical Biochemistry</i> , 2017, 537, 84-92.	1.1	18
752	Critical roles of <i>hMAGEA2</i> in induced pluripotent stem cell pluripotency, proliferation, and differentiation. <i>Cell Biochemistry and Function</i> , 2017, 35, 392-400.	1.4	3
753	Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?. <i>Trends in Cancer</i> , 2017, 3, 698-712.	3.8	85
754	D40/KNL1/CASC5 and autosomal recessive primary microcephaly. <i>Congenital Anomalies (discontinued)</i> , 2017, 57, 191-196.	0.3	4
755	Germline factor DDX 4 functions in blood-derived cancer cell phenotypes. <i>Cancer Science</i> , 2017, 108, 1612-1619.	1.7	37
756	Alterations in Ca ²⁺ Signalling via ER-Mitochondria Contact Site Remodelling in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 997, 225-254.	0.8	35
757	A pathology atlas of the human cancer transcriptome. <i>Science</i> , 2017, 357, .	6.0	2,570
758	Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. <i>Cell</i> , 2017, 171, 1559-1572.e20.	13.5	200

#	ARTICLE	IF	CITATIONS
759	An ensemble method integrated with miRNA expression data for predicting miRNA targets in stomach adenocarcinoma. <i>Cancer Biomarkers</i> , 2017, 20, 617-625.	0.8	6
760	Human spermatogonial markers. <i>Stem Cell Research</i> , 2017, 25, 300-309.	0.3	38
761	A cis-eQTL genetic variant of the cancer-associated testis gene CCDC116 is associated with risk of multiple cancers. <i>Human Genetics</i> , 2017, 136, 987-997.	1.8	7
762	The unique C- and N-terminal sequences of Metallothionein isoform 3 mediate growth inhibition and Vectorial active transport in MCF-7 cells. <i>BMC Cancer</i> , 2017, 17, 369.	1.1	3
763	Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts. <i>Hormones and Cancer</i> , 2017, 8, 4-15.	4.9	22
764	The testis-specific USP26 is a deubiquitinating enzyme of the ubiquitin ligase Mdm2. <i>Biochemical and Biophysical Research Communications</i> , 2017, 482, 106-111.	1.0	18
765	Epigenetic Basis of Human Cancer. , 2017, , 83-102.		1
766	The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signaling. <i>Oncogene</i> , 2017, 36, 1476-1486.	2.6	25
767	TWIST1 upregulates the MAGEA4 oncogene. <i>Molecular Carcinogenesis</i> , 2017, 56, 877-885.	1.3	32
768	The ER-mitochondria couple: In life and death from steroidogenesis to tumorigenesis. <i>Molecular and Cellular Endocrinology</i> , 2017, 441, 176-184.	1.6	17
769	The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients. <i>Expert Review of Vaccines</i> , 2018, 17, 1-8.	2.0	34
770	Progress in Vaccine Therapies for Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 315-330.	0.8	11
771	Immunotherapy in ovarian cancer. <i>Annals of Oncology</i> , 2017, 28, viii1-viii7.	0.6	276
772	Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. <i>The Cochrane Library</i> , 2017, 12, CD011300.	1.5	47
773	Autoantibody Repertoire in APECED Patients Targets Two Distinct Subgroups of Proteins. <i>Frontiers in Immunology</i> , 2017, 8, 976.	2.2	48
774	Piwil2-transfected human fibroblasts are cancer stem cell-like and genetically unstable. <i>Oncotarget</i> , 2017, 8, 12259-12271.	0.8	17
775	New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don't Know. <i>Epigenomes</i> , 2017, 1, 3.	0.8	6
776	MAGE-A Antigens and Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2017, 4, 18.	1.2	54

#	ARTICLE	IF	CITATIONS
777	Melanoma: tumor microenvironment and new treatments. <i>Anais Brasileiros De Dermatologia</i> , 2017, 92, 156-166.	0.5	35
778	Design of nanoparticle structures for cancer immunotherapy. , 2017, , 307-328.		1
779	Functional interaction between co-expressed MAGE-A proteins. <i>PLoS ONE</i> , 2017, 12, e0178370.	1.1	11
780	Overexpression of MAGEA2 has a prognostic significance and is a potential therapeutic target for patients with lung cancer. <i>International Journal of Oncology</i> , 2017, 50, 2154-2170.	1.4	9
781	High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2017, 52, 219-230.	1.4	15
782	Targeting the epigenome in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2017, 6, 350-365.	1.3	36
783	Association of MAGE A1-6 Expression with Lung Cancer Progression. <i>Journal of Cancer</i> , 2017, 8, 1324-1329.	1.2	9
784	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. <i>Journal of Clinical Oncology</i> , 2017, 35, 3322-3329.	0.8	204
785	Oncogenesis by Unprogrammed Gene Activation: A Critical Evaluation of Cancer Testis Genes. , 2017, , .		1
786	Genome-wide identification of cancer/testis genes and their association with prognosis in a pan-cancer analysis. <i>Oncotarget</i> , 2017, 8, 92966-92977.	0.8	43
787	Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. <i>Nature Communications</i> , 2018, 9, 785.	5.8	29
788	Targeting Neoantigens for Personalised Immunotherapy. <i>BioDrugs</i> , 2018, 32, 99-109.	2.2	11
789	A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. <i>Cell Death and Disease</i> , 2018, 9, 379.	2.7	15
790	Expression of C19MC miRNAs in HCC associates with stem-cell features and the cancer-testis genes signature. <i>Digestive and Liver Disease</i> , 2018, 50, 583-593.	0.4	15
791	Molecular Phenotyping of Telomerized Human Bone Marrow Skeletal Stem Cells Reveals a Genetic Program of Enhanced Proliferation and Maintenance of Differentiation Responses. <i>JBMR Plus</i> , 2018, 2, 257-267.	1.3	21
792	Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. <i>Blood</i> , 2018, 131, 2490-2499.	0.6	21
793	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. <i>Cell</i> , 2018, 173, 624-633.e8.	13.5	113
794	Infectious, inflammatory and "autoimmune" male factor infertility: how do rodent models inform clinical practice?. <i>Human Reproduction Update</i> , 2018, 24, 416-441.	5.2	188

#	ARTICLE	IF	CITATIONS
795	Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma. <i>Molecular Cancer Research</i> , 2018, 16, 623-633.	1.5	10
796	Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2018, 46, 492-497.	0.7	6
797	Cancer/testis antigen Plac1 promotes invasion and metastasis of breast cancer through Furin/NICD/PTEN signaling pathway. <i>Molecular Oncology</i> , 2018, 12, 1233-1248.	2.1	26
798	MAGE-A antigens as targets for cancer immunotherapy. <i>Cancer Treatment Reviews</i> , 2018, 67, 54-62.	3.4	51
799	Regulation and Dysregulation of Chromosome Structure in Cancer. <i>Annual Review of Cancer Biology</i> , 2018, 2, 21-40.	2.3	26
800	MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer. <i>Clinical Oral Investigations</i> , 2018, 22, 1477-1486.	1.4	13
801	Epigenetic Events in Lung Cancer. , 2018, , 104-116.e5.		1
802	Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. <i>Oncologist</i> , 2018, 23, 71-83.	1.9	45
803	Cancer/testis gene PIWIL1 promotes cell proliferation, migration, and invasion in lung adenocarcinoma. <i>Cancer Medicine</i> , 2018, 7, 157-166.	1.3	45
804	Mechanisms of Tumor Cell Intrinsic Immune Evasion. <i>Annual Review of Cancer Biology</i> , 2018, 2, 213-228.	2.3	65
806	Cellular Therapy. <i>Current Cancer Research</i> , 2018, , 133-184.	0.2	0
807	Impact of protamine I on colon cancer proliferation, invasion, migration, diagnosis and prognosis. <i>Biological Chemistry</i> , 2018, 399, 265-275.	1.2	7
808	Biomarker Discovery via Optimal Bayesian Feature Filtering for Structured Multiclass Data. , 2018, , .		3
809	Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin. <i>Oncology Letters</i> , 2018, 15, 9480-9486.	0.8	8
810	Perspective: cancer vaccines in the era of immune checkpoint blockade. <i>Mammalian Genome</i> , 2018, 29, 703-713.	1.0	20
811	Expression of the POTE gene family in human ovarian cancer. <i>Scientific Reports</i> , 2018, 8, 17136.	1.6	21
812	Cytoskeleton Structure in Mouse Sperm and Testes After 30 Days of Hindlimb Unloading and 12 Hours of Recovery. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 375-392.	1.1	17
813	Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. <i>Journal of Immunology Research</i> , 2018, 2018, 1-9.	0.9	75

#	ARTICLE	IF	CITATIONS
814	Possible predictive role of cancer/testis antigens in breast ductal carcinoma <i>in situ</i> . <i>Oncology Letters</i> , 2018, 16, 7245-7255.	0.8	3
815	The role of Cancer/Testis Antigens in Multiple Myeloma pathogenesis and their application in disease monitoring and therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 17-26.	2.0	11
816	Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. <i>Journal of Clinical Medicine</i> , 2018, 7, 156.	1.0	10
817	Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors. <i>Trends in Cancer</i> , 2018, 4, 701-712.	3.8	81
818	Abnormal gametogenesis induced by p53 deficiency promotes tumor progression and drug resistance. <i>Cell Discovery</i> , 2018, 4, 54.	3.1	11
819	A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5928-5938.	1.6	128
820	Personalized vaccination against ovarian cancer: what are the possibilities?. <i>Expert Review of Vaccines</i> , 2018, 17, 955-958.	2.0	7
821	Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes. <i>Cellular Immunology</i> , 2018, 334, 78-86.	1.4	14
822	Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. <i>Cell Reports</i> , 2018, 25, 1066-1080.e8.	2.9	239
823	Generation of a cancer testis antigen mCherry reporter HCT116 colorectal carcinoma cell line. <i>Heliyon</i> , 2018, 4, e00858.	1.4	0
824	Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 1025-1039.	0.9	11
825	Post-transcriptional regulation of cancer/testis antigen MAGEC2 expression by TRIM28 in tumor cells. <i>BMC Cancer</i> , 2018, 18, 971.	1.1	7
826	Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2018, 9, 1118.	1.6	126
827	The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells. <i>Scientific Reports</i> , 2018, 8, 15304.	1.6	43
828	B cells and antibody production in melanoma. <i>Mammalian Genome</i> , 2018, 29, 790-805.	1.0	19
829	Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?. <i>Breast</i> , 2018, 42, 68-73.	0.9	21
830	Epigenetic regulation of MAGE family in human cancer progression-DNA methylation, histone modification, and non-coding RNAs. <i>Clinical Epigenetics</i> , 2018, 10, 115.	1.8	44
831	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolmmunology</i> , 2018, 7, e1511506.	2.1	121

#	ARTICLE	IF	CITATIONS
832	Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. <i>Cell</i> , 2018, 175, 159-170.e16.	13.5	127
833	The potential immune-eliciting cancer testis antigens in colorectal cancer. <i>Immunotherapy</i> , 2018, 10, 1093-1104.	1.0	6
834	Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy. <i>Seminars in Cancer Biology</i> , 2018, 53, 75-89.	4.3	90
835	Genome-Wide RNAi Screen Identify Melanoma-Associated Antigen Mageb3 Involved in X Chromosome Inactivation. <i>Journal of Molecular Biology</i> , 2018, 430, 2734-2746.	2.0	4
836	Dynamic Copy Number Evolution of X- and Y-Linked Ampliconic Genes in Human Populations. <i>Genetics</i> , 2018, 209, 907-920.	1.2	32
837	Nature of tumour rejection antigens in ovarian cancer. <i>Immunology</i> , 2018, 155, 202-210.	2.0	12
838	Computational prediction of vaccine potential epitopes and 3-dimensional structure of XAGE-1b for non-small cell lung cancer immunotherapy. <i>Biomedical Journal</i> , 2018, 41, 118-128.	1.4	10
839	Targeted photodynamic therapy of cancer using a novel gallium (III) tris (ethoxycarbonyl) corrole conjugatedâ€mAb directed against cancer/testis antigens 83. <i>Cancer Medicine</i> , 2018, 7, 3057-3065.	1.3	25
840	YTH-RNA-binding protein prevents deleterious expression of meiotic proteins by tethering their mRNAs to nuclear foci. <i>ELife</i> , 2018, 7, .	2.8	32
841	Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. , 2018, 6, 38.		11
842	Peptide Delivery Systems for Cancer Vaccines. <i>Advanced Therapeutics</i> , 2018, 1, 1800060.	1.6	30
843	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmetteâ€GuÃ©rin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 411.	2.2	49
844	NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. <i>Frontiers in Immunology</i> , 2018, 9, 947.	2.2	261
845	Dual TGFâ€² and PDâ€1 blockade synergistically enhances MAGEâ€A3â€specific CD8⁺ T cell response in esophageal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 2561-2574.	2.3	68
846	STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1787.	1.8	106
847	The dualistic origin of human tumors. <i>Seminars in Cancer Biology</i> , 2018, 53, 1-16.	4.3	105
848	Gender and Dermatology. , 2018, , .		4
849	Depletion of DNMT1 in differentiated human cells highlights key classes of sensitive genes and an interplay with polycomb repression. <i>Epigenetics and Chromatin</i> , 2018, 11, 12.	1.8	18

#	ARTICLE	IF	CITATIONS
850	Biology and Sex Disparities in Melanoma Outcomes. , 2018, , 193-213.		0
851	Predicting Antigen Presentation“What Could We Learn From a Million Peptides?. Frontiers in Immunology, 2018, 9, 1716.	2.2	159
852	ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells. , 2018, 59, 132.		20
853	Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment development. Oncogene, 2018, 37, 5694-5700.	2.6	45
854	Systematic identification of cancer-specific MHC-binding peptides with RAVEN. Oncolmmunology, 2018, 7, e1481558.	2.1	16
855	Methods for improving the immunogenicity and efficacy of cancer vaccines. Expert Opinion on Biological Therapy, 2018, 18, 765-784.	1.4	13
856	Optimal Bayesian Filtering for Biomarker Discovery: Performance and Robustness. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019, 17, 1-1.	1.9	6
857	Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles. Scientific Reports, 2019, 9, 11632.	1.6	20
858	Post-replication repair: Rad5/HLTF regulation, activity on undamaged templates, and relationship to cancer. Critical Reviews in Biochemistry and Molecular Biology, 2019, 54, 301-332.	2.3	18
859	Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?. Cancers, 2019, 11, 984.	1.7	78
860	Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma. EBioMedicine, 2019, 46, 54-65.	2.7	31
861	Retention of paternal DNA methylome in the developing zebrafish germline. Nature Communications, 2019, 10, 3054.	5.8	99
862	Smoking Induced Extracellular Vesicles Release and Their Distinct Properties in Non-Small Cell Lung Cancer. Journal of Cancer, 2019, 10, 3435-3443.	1.2	57
863	Testes and duct deferens of mice during space flight: cytoskeleton structure, sperm-specific proteins and epigenetic events. Scientific Reports, 2019, 9, 9730.	1.6	10
864	Intracellular targets as source for cleaner targets for the treatment of solid tumors. Biochemical Pharmacology, 2019, 168, 275-284.	2.0	8
865	Functional and mechanistic studies reveal MAGEA3 as a pro-survival factor in pancreatic cancer cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 294.	3.5	15
866	Effect of KNL1 on the proliferation and apoptosis of colorectal cancer cells. Technology in Cancer Research and Treatment, 2019, 18, 153303381985866.	0.8	24
867	TuBA: Tunable biclustering algorithm reveals clinically relevant tumor transcriptional profiles in breast cancer. GigaScience, 2019, 8, .	3.3	6

#	ARTICLE	IF	CITATIONS
868	Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109542.	2.5	39
869	Hypomethylation-activated cancer testis gene SPANXC promotes cell metastasis in lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7261-7267.	1.6	1
870	Molecular and Functional Characterization of the Somatic PIWIL1/piRNA Pathway in Colorectal Cancer Cells. <i>Cells</i> , 2019, 8, 1390.	1.8	16
871	A cis eQTL genetic variant in PLK4 confers high risk of hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019, 8, 6476-6484.	1.3	11
872	MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. <i>Journal of Hematology and Oncology</i> , 2019, 12, 106.	6.9	36
873	Expressions of melanoma-associated antigen A1 as a prognostic factor in Chinese patients with resectable oesophageal squamous cell carcinoma. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 29, 510-516.	0.5	4
874	Tumor neoantigens: from basic research to clinical applications. <i>Journal of Hematology and Oncology</i> , 2019, 12, 93.	6.9	266
875	Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2071-2083.	0.5	33
876	Prognostic roles of MAGE family members in breast cancer based on KM Plotter Data. <i>Oncology Letters</i> , 2019, 18, 3501-3516.	0.8	20
877	The Cancer Aneuploidy Paradox: In the Light of Evolution. <i>Genes</i> , 2019, 10, 83.	1.0	41
878	lncRNA MIR503HG functioned as a tumor suppressor and inhibited cell proliferation, metastasis and epithelial-mesenchymal transition in bladder cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 10821-10829.	1.2	32
879	Regulation of MAGEA3/6 by the CRL4 DCAF12 ubiquitin ligase and nutrient availability. <i>EMBO Reports</i> , 2019, 20, e47352.	2.0	26
880	Cancer testis antigens as biomarkers for Merkel cell carcinoma: Pitfalls and opportunities. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 748-752.	0.7	9
881	In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens. <i>BioImpacts</i> , 2019, 9, 45-56.	0.7	30
883	Linkage between EMT and stemness state through molecular association between TWIST1 and NY-ESO1 in esophageal squamous cell carcinoma. <i>Biochimie</i> , 2019, 163, 84-93.	1.3	12
884	PLAC1: biology and potential application in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1039-1058.	2.0	16
885	Meiotic gene activation in somatic and germ cell tumours. <i>Andrology</i> , 2019, 7, 415-427.	1.9	20
886	Comprehensive characterization of cancer testis genes in testicular germ cell tumor. <i>Cancer Medicine</i> , 2019, 8, 3511-3519.	1.3	22

#	ARTICLE	IF	CITATIONS
887	Aberrant expression of select piRNA-pathway genes does not reactivate piRNA silencing in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11111-11112.	3.3	38
888	Cancer stemness, intratumoral heterogeneity, and immune response across cancers. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9020-9029.	3.3	372
889	Hypomethylation-mediated activation of cancer/testis antigen KIF20A facilitates hepatocellular carcinoma progression through activating the Notch1/Hes1 signalling. Cell Proliferation, 2019, 52, e12581.	2.4	25
890	Cervical, Ovarian and Endometrial Tumor Markers: Potential Clinical Value. Seminars in Ultrasound, CT and MRI, 2019, 40, 350-357.	0.7	9
891	GAGE7B promotes tumor metastasis and growth via activating the p38 β /pMAPKAPK2/pHSP27 pathway in gastric cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 124.	3.5	17
892	Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects. Translational Oncology, 2019, 12, 733-738.	1.7	44
893	Gene amplification derived a cancer-testis long noncoding RNA PCAT6 regulates cell proliferation and migration in hepatocellular carcinoma. Cancer Medicine, 2019, 8, 3017-3025.	1.3	21
894	Overexpression and Implications of Melanoma-associated Antigen A12 in Pathogenesis of Human Cutaneous Squamous Cell Carcinoma. Anticancer Research, 2019, 39, 1849-1857.	0.5	11
895	ZCCHC13-mediated induction of human liver cancer is associated with the modulation of DNA methylation and the AKT/ERK signaling pathway. Journal of Translational Medicine, 2019, 17, 108.	1.8	20
896	A conserved dimer interface connects ERH and YTH family proteins to promote gene silencing. Nature Communications, 2019, 10, 251.	5.8	36
897	Epigenetic activation of POTE genes in ovarian cancer. Epigenetics, 2019, 14, 185-197.	1.3	24
898	Turning the corner on therapeutic cancer vaccines. Npj Vaccines, 2019, 4, 7.	2.9	490
899	Expression of Kita-Kyushu Lung Cancer Antigen-1 as Detected by a Novel Monoclonal Antibody in Gastric Cancer. Anticancer Research, 2019, 39, 6259-6263.	0.5	4
900	Sertoli cell-only phenotype and scRNA-seq define PRAMEF12 as a factor essential for spermatogenesis in mice. Nature Communications, 2019, 10, 5196.	5.8	35
901	Validation of immunogenic PASD1 peptides against HLA-A*24:02 colorectal cancer. Immunotherapy, 2019, 11, 1205-1219.	1.0	3
902	Programmed DNA elimination of germline development genes in songbirds. Nature Communications, 2019, 10, 5468.	5.8	66
903	Overexpression of cancer-testis antigen melanoma-associated antigen A1 in lung cancer: A novel biomarker for prognosis, and a possible target for immunotherapy. Journal of Cellular Physiology, 2019, 234, 12080-12086.	2.0	28
904	Recent Advances in Anti-cancer Protein/Peptide Delivery. Bioconjugate Chemistry, 2019, 30, 305-324.	1.8	113

#	ARTICLE	IF	CITATIONS
905	Improving TCR affinity on 293T cells. <i>Journal of Immunological Methods</i> , 2019, 466, 1-8.	0.6	12
906	Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets. <i>Journal of Ovarian Research</i> , 2019, 12, 1.	1.3	69
907	Cancer Epigenomics on Precision Medicine and Immunotherapy. , 2019, , 483-503.		0
908	A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma. <i>Oncogene</i> , 2019, 38, 1611-1624.	2.6	61
909	A novel testis-specific long noncoding RNA, <i>Tesra</i> , activates the <i>Prss42/Tessp-2</i> gene during mouse spermatogenesis. <i>Biology of Reproduction</i> , 2019, 100, 833-848.	1.2	19
910	Strong Expression of Cancer-testis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer. <i>Urologia Internationalis</i> , 2019, 102, 77-82.	0.6	6
912	Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder. <i>Pathology and Oncology Research</i> , 2019, 25, 191-199.	0.9	17
913	MAGE-A4 and MAGE-A1 Immunohistochemical Expression in High-grade Endometrial Cancer. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 59-65.	0.9	5
914	Novel therapeutic strategies for spinal osteosarcomas. <i>Seminars in Cancer Biology</i> , 2020, 64, 83-92.	4.3	32
915	The "life code": A theory that unifies the human life cycle and the origin of human tumors. <i>Seminars in Cancer Biology</i> , 2020, 60, 380-397.	4.3	70
916	Decreasing New York esophageal squamous cell carcinoma 1 expression inhibits multiple myeloma growth and osteolytic lesions. <i>Journal of Cellular Physiology</i> , 2020, 235, 2183-2194.	2.0	6
917	Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application. <i>Cancer Letters</i> , 2020, 479, 54-60.	3.2	26
918	Aberrantly enhanced melanoma-associated antigen (MAGE)-A3 expression facilitates cervical cancer cell proliferation and metastasis via actuating Wnt signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2020, 122, 109710.	2.5	19
919	Expression of tumor-associated antigens in breast cancer subtypes. <i>Breast</i> , 2020, 49, 202-209.	0.9	24
920	Autoimmune Orchitis and Autoimmune Oophoritis. , 2020, , 1235-1251.		0
921	Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. <i>Seminars in Cancer Biology</i> , 2020, 65, 114-122.	4.3	45
922	Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1359-1371.	3.2	90
923	TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy. <i>Life Sciences</i> , 2020, 241, 117171.	2.0	7

#	ARTICLE	IF	CITATIONS
924	The Functionally Unannotated Proteome of Human Male Tissues: A Shared Resource to Uncover New Protein Functions Associated with Reproductive Biology. <i>Journal of Proteome Research</i> , 2020, 19, 4782-4794.	1.8	10
925	PIWI-interacting RNAs in human cancer. <i>Seminars in Cancer Biology</i> , 2021, 75, 15-28.	4.3	12
926	Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 387-397.	2.5	4
927	Structural basis for substrate recognition and chemical inhibition of oncogenic MAGE ubiquitin ligases. <i>Nature Communications</i> , 2020, 11, 4931.	5.8	17
928	Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells. <i>BMC Cancer</i> , 2020, 20, 673.	1.1	11
929	T cell receptor therapy against melanoma—Immunotherapy for the future?. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12927.	1.3	8
930	Humoral immune responses: Unsung heroes of the war on cancer. <i>Seminars in Immunology</i> , 2020, 49, 101419.	2.7	11
931	In Search of TGCT Biomarkers: A Comprehensive In Silico and Histopathological Analysis. <i>Disease Markers</i> , 2020, 2020, 1-18.	0.6	7
932	Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 3529.	1.7	60
933	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
934	Why the Outcome of Anti-Tumor Immune Responses is Heterogeneous: A Novel Idea in the Context of Immunological Heterogeneity in Cancers. <i>BioEssays</i> , 2020, 42, 2000024.	1.2	9
935	Tissue-Specific Regulation of the Wnt/ β -Catenin Pathway by PAGE4 Inhibition of Tankyrase. <i>Cell Reports</i> , 2020, 32, 107922.	2.9	7
936	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. <i>Nature</i> , 2020, 585, 107-112.	13.7	526
937	Part 2: Deregulated Expressions of PIWI Proteins and piRNAs as New Candidate Biomarkers and Potential Therapeutic Tools in Cancer. , 0, , .		1
938	Cancer-Related Increases and Decreases in Calcium Signaling at the Endoplasmic Reticulum-Mitochondria Interface (MAMs). <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020, , 153-193.	0.9	13
939	Context-Dependent Tumorigenic Effect of Testis-Specific Mitochondrial Protein Tiny Tim 2 in <i>Drosophila</i> Somatic Epithelia. <i>Cells</i> , 2020, 9, 1842.	1.8	0
940	Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach. <i>Oncolmmunology</i> , 2020, 9, 1824642.	2.1	6
941	RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H. <i>EBioMedicine</i> , 2020, 61, 103067.	2.7	27

#	ARTICLE	IF	CITATIONS
942	Selecting Target Antigens for Cancer Vaccine Development. <i>Vaccines</i> , 2020, 8, 615.	2.1	59
943	Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 1322-1334.	1.6	45
944	Reduced cytoplasmic expression of MAGE-A2 predicts tumor aggressiveness and survival: an immunohistochemical analysis. <i>World Journal of Urology</i> , 2020, 39, 1831-1843.	1.2	2
945	CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens. <i>Frontiers in Immunology</i> , 2020, 11, 1568.	2.2	20
946	Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094427.	0.8	4
947	Tumors Widely Express Hundreds of Embryonic Germline Genes. <i>Cancers</i> , 2020, 12, 3812.	1.7	12
948	Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma. <i>Cancers</i> , 2020, 12, 3612.	1.7	17
949	Immunomodulatory Effects of Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8151.	1.8	34
950	Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8324.	1.8	5
951	The polycomb group protein PCGF6 mediates germline gene silencing by recruiting histone-modifying proteins to target gene promoters. <i>Journal of Biological Chemistry</i> , 2020, 295, 9712-9724.	1.6	20
952	Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors. <i>American Journal of Surgical Pathology</i> , 2020, 44, 893-900.	2.1	70
953	Sperm Originated Chromatin Imprints and lincRNAs in Organismal Development and Cancer. <i>IScience</i> , 2020, 23, 101165.	1.9	2
954	Cancer immunotherapy using T-cell receptor engineered T cell. <i>Annals of Blood</i> , 2020, 5, 5-5.	0.4	4
955	Nanos3, a cancer-germline gene, promotes cell proliferation, migration, chemoresistance, and invasion of human glioblastoma. <i>Cancer Cell International</i> , 2020, 20, 197.	1.8	7
956	Stem-like Mesenchymal Signature Cell Genes Detected in Heterogeneous Circulating Melanoma Cells Correlate With Disease Stage in Melanoma Patients. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 92.	1.6	8
957	piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. <i>Nature Cell Biology</i> , 2020, 22, 425-438.	4.6	49
958	Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. <i>Cancers</i> , 2020, 12, 689.	1.7	14
959	Systematic analysis of genetic variants in cancer-testis genes identified two novel lung cancer susceptibility loci in Chinese population. <i>Journal of Cancer</i> , 2020, 11, 1985-1993.	1.2	2

#	ARTICLE	IF	CITATIONS
960	Immunogenomic Landscape of Hematological Malignancies. <i>Cancer Cell</i> , 2020, 38, 380-399.e13.	7.7	109
961	Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process. <i>Cancers</i> , 2020, 12, 1660.	1.7	29
962	Cancer Epigenetics, Tumor Immunity, and Immunotherapy. <i>Trends in Cancer</i> , 2020, 6, 580-592.	3.8	166
963	Evolutionary Dynamics of the POTE Gene Family in Human and Nonhuman Primates. <i>Genes</i> , 2020, 11, 213.	1.0	7
964	LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement. <i>Neuro-Oncology</i> , 2020, 22, 1315-1326.	0.6	17
965	The clinical potential of gene editing as a tool to engineer cell-based therapeutics. <i>Clinical and Translational Medicine</i> , 2020, 9, 15.	1.7	56
966	A Cancer-Specific Ubiquitin Ligase Drives mRNA Alternative Polyadenylation by Ubiquitinating the mRNA 3' End Processing Complex. <i>Molecular Cell</i> , 2020, 77, 1206-1221.e7.	4.5	52
967	HSF2BP negatively regulates homologous recombination in DNA interstrand crosslink repair. <i>Nucleic Acids Research</i> , 2020, 48, 2442-2456.	6.5	22
968	Stromal-epithelial interactions in prostate cancer: Overexpression of PAGE4 in stromal cells inhibits the invasive ability of epithelial cells. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 4406-4418.	1.2	7
969	Tumor immune microenvironment in head and neck cancers. <i>Molecular Carcinogenesis</i> , 2020, 59, 766-774.	1.3	90
970	Identification of primordial germ cell-like cells as liver metastasis initiating cells in mouse tumour models. <i>Cell Discovery</i> , 2020, 6, 15.	3.1	4
971	The ectopic expression of meiCT genes promotes meiomitosis and may facilitate carcinogenesis. <i>Cell Cycle</i> , 2020, 19, 837-854.	1.3	17
972	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
973	CTCF and CTCFL in cancer. <i>Current Opinion in Genetics and Development</i> , 2020, 61, 44-52.	1.5	48
974	Crosstalk between Stress Granules, Exosomes, Tumour Antigens, and Immune Cells: Significance for Cancer Immunity. <i>Vaccines</i> , 2020, 8, 172.	2.1	10
975	Cellular Therapy and Cytokine Treatments for Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 129-144.	0.9	11
976	Effect of genistein, daidzein and coumestrol on sex-related genes expression in Russian sturgeon (<i>Acipenser gueldenstaedtii</i>). <i>Aquaculture</i> , 2021, 530, 735872.	1.7	5
977	MageC2 protein is upregulated by oncogenic activation of MAPK pathway and causes impairment of the p53 transactivation function. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 118918.	1.9	3

#	ARTICLE	IF	CITATIONS
978	Cancer/Testis Antigens into mitochondria: a hub between spermatogenesis, tumorigenesis and mitochondrial physiology adaptation. <i>Mitochondrion</i> , 2021, 56, 73-81.	1.6	7
979	Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 476-487.	5.7	9
980	The X chromosome and male infertility. <i>Human Genetics</i> , 2021, 140, 203-215.	1.8	40
981	Cancer Vaccines: Antigen Selection Strategy. <i>Vaccines</i> , 2021, 9, 85.	2.1	30
982	The patterns of antisense long non-coding RNAs regulating corresponding sense genes in human cancers. <i>Journal of Cancer</i> , 2021, 12, 1499-1506.	1.2	14
983	Synaptonemal complex proteins modulate the level of genome integrity in cancers. <i>Cancer Science</i> , 2021, 112, 989-996.	1.7	17
984	The use of immunotherapy for treatment of chemoresistant ovarian cancer. , 2021, , 79-96.		0
985	Unraveling the Regulation of Cancer/Testis Antigens in Tumorigenesis Through an Analysis of Normal Germ Cell Development in Rodents. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1288, 69-93.	0.8	0
986	Immunotherapy in colorectal cancer. <i>Advances in Cancer Research</i> , 2021, 151, 137-196.	1.9	18
987	The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 584024.	1.3	7
988	Deficiency of TBL1XR1 causes asthenozoospermia. <i>Andrologia</i> , 2021, 53, e13980.	1.0	3
989	Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 346-360.	0.8	3
990	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. <i>Future Science OA</i> , 2021, 7, FSO662.	0.9	1
991	Sperm proteins and cancerâ€™testis antigens are released by the seminiferous tubules in mice and men. <i>FASEB Journal</i> , 2021, 35, e21397.	0.2	14
992	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 448-458.	0.8	15
993	Tumor models in various <i>Drosophila</i> tissues. <i>WIREs Mechanisms of Disease</i> , 2021, 13, e1525.	1.5	13
994	Functional contribution of <i>DCLKs</i> in sea urchin development. <i>Developmental Dynamics</i> , 2021, 250, 1160-1172.	0.8	1
995	KK-LC-1 may be an effective prognostic biomarker for gastric cancer. <i>BMC Cancer</i> , 2021, 21, 267.	1.1	5

#	ARTICLE	IF	CITATIONS
996	Small Non-Coding-RNA in Gynecological Malignancies. <i>Cancers</i> , 2021, 13, 1085.	1.7	20
997	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	21.5	208
998	Therapeutic applications of the cancer immunoediting hypothesis. <i>Seminars in Cancer Biology</i> , 2022, 78, 63-77.	4.3	29
999	Meiotic nuclear divisions 1 (MND1) fuels cell cycle progression by activating a KLF6/E2F1 positive feedback loop in lung adenocarcinoma. <i>Cancer Communications</i> , 2021, 41, 492-510.	3.7	17
1000	Cancer/testis antigens: from serology to mRNA cancer vaccine. <i>Seminars in Cancer Biology</i> , 2021, 76, 218-231.	4.3	27
1001	The foundational framework of tumors: Gametogenesis, p53, and cancer. <i>Seminars in Cancer Biology</i> , 2022, 81, 193-205.	4.3	5
1002	Epigenetic transgenerational inheritance, gametogenesis and germline development. <i>Biology of Reproduction</i> , 2021, 105, 570-592.	1.2	32
1003	The PRAME family of cancer testis antigens is essential for germline development and gametogenesis. <i>Biology of Reproduction</i> , 2021, 105, 290-304.	1.2	19
1004	Immunohistochemical Detection of Cancer-Testis Antigen PRAME. <i>International Journal of Surgical Pathology</i> , 2021, 29, 826-835.	0.4	14
1005	Expression and Prognostic Significance of Cancer/Testis Antigens, MAGE-E1, GAGE, and SOX-6, in Glioblastoma: An Immunohistochemistry Evaluation. <i>Iranian Journal of Pathology</i> , 2021, 16, 128-136.	0.2	1
1007	Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).. , 2021, 9, e002694.		19
1008	The Role of the Meiotic Component in Reproduction of B-RAF-Mutated Melanoma: A Review and Brainstorming Session. , 0, , .		2
1009	Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions. <i>Vaccines</i> , 2021, 9, 535.	2.1	38
1010	Emerging roles of cancer-testis antigens, semenogelin 1 and 2, in neoplastic cells. <i>Cell Death Discovery</i> , 2021, 7, 97.	2.0	5
1011	MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6741.	1.8	28
1012	Placenta-specific protein 1 promotes cell proliferation via the AKT/GSK β ² /cyclin D1 signaling pathway in gastric cancer. <i>IUBMB Life</i> , 2021, 73, 1131-1141.	1.5	4
1013	Targeting cancer testis antigens in synovial sarcoma. , 2021, 9, e002072.		16
1014	PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions. <i>Surgical Pathology Clinics</i> , 2021, 14, 165-175.	0.7	30

#	ARTICLE	IF	CITATIONS
1015	The combined action of CTCF and its testis-specific paralog BORIS is essential for spermatogenesis. <i>Nature Communications</i> , 2021, 12, 3846.	5.8	18
1016	Ligand-Receptor Interactions Elucidate Sex-Specific Pathways in the Trajectory From Primordial Germ Cells to Gonadotropin-Releasing Hormone During Human Development. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 661243.	1.8	13
1017	T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 102.	6.9	64
1018	Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 690499.	2.2	59
1019	Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?. <i>Frontiers in Immunology</i> , 2021, 12, 634031.	2.2	2
1020	Combined RNA/tissue profiling identifies novel Cancer/testis genes. <i>Molecular Oncology</i> , 2021, 15, 3003-3023.	2.1	3
1021	Multimiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer. <i>Scientific Reports</i> , 2021, 11, 12172.	1.6	12
1022	ACRBP (Sp32) is involved in priming sperm for the acrosome reaction and the binding of sperm to the zona pellucida in a porcine model. <i>PLoS ONE</i> , 2021, 16, e0251973.	1.1	14
1023	Inactivation of testis-specific gene C4orf46 is dispensable for spermatogenesis and fertility in mouse. <i>Mammalian Genome</i> , 2021, 32, 364-370.	1.0	4
1024	Genomic architecture constrained placental mammal X Chromosome evolution. <i>Genome Research</i> , 2021, 31, 1353-1365.	2.4	16
1025	Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. , 2021, 223, 107892.		11
1026	Large palindromes on the primate X Chromosome are preserved by natural selection. <i>Genome Research</i> , 2021, 31, 1337-1352.	2.4	10
1027	Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies. <i>Translational Lung Cancer Research</i> , 2021, 10, 3079-3092.	1.3	6
1029	Unusual aggregation property of recombinantly expressed cancer-testis antigens in mammalian cells. <i>Journal of Biochemistry</i> , 2021, 170, 435-443.	0.9	2
1030	Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8035.	1.8	30
1031	Development of neoantigens: from identification in cancer cells to application in cancer vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 941-955.	2.0	11
1032	Cancer-Testis Antigens in Triple-Negative Breast Cancer: Role and Potential Utility in Clinical Practice. <i>Cancers</i> , 2021, 13, 3875.	1.7	9
1033	Androgen signaling connects short isoform production to breakpoint formation at Ewing sarcoma breakpoint region 1. <i>NAR Cancer</i> , 2021, 3, zcab033.	1.6	3

#	ARTICLE	IF	CITATIONS
1034	H2A.B is a cancer/testis factor involved in the activation of ribosome biogenesis in Hodgkin lymphoma. EMBO Reports, 2021, 22, e52462.	2.0	8
1035	Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?. Epigenomes, 2021, 5, 16.	0.8	5
1036	GAGE mediates radio resistance in cervical cancers via the regulation of chromatin accessibility. Cell Reports, 2021, 36, 109621.	2.9	10
1037	Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy. Cancers, 2021, 13, 4245.	1.7	13
1038	Somatic Sex: On the Origin of Neoplasms With Chromosome Counts in Uneven Ploidy Ranges. Frontiers in Cell and Developmental Biology, 2021, 9, 631946.	1.8	6
1040	A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer. Clinica Chimica Acta, 2021, 519, 51-59.	0.5	10
1041	A novel era of cancer/testis antigen in cancer immunotherapy. International Immunopharmacology, 2021, 98, 107889.	1.7	36
1042	Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma. Oncotarget, 2021, 12, 2051-2067.	0.8	0
1043	mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. Vaccines, 2021, 9, 1060.	2.1	39
1044	Cancer testis antigens and genomic instability: More than immunology. DNA Repair, 2021, 108, 103214.	1.3	14
1045	Personalized cancer immunotherapy. , 2022, , 399-426.		0
1046	Increased Melanoma-Associated Antigen C2 Expression Affords Resistance to Apoptotic Death in Suspension-Cultured Tumor Cells. Journal of Breast Cancer, 2021, 24, 138.	0.8	1
1048	Expression of Cancer-testis Antigens in Adenoid Cystic Carcinoma of the Salivary Glands Correlates with Clinical Outcomes. Journal of Hard Tissue Biology, 2021, 30, 283-290.	0.2	0
1049	The cancer-testis gene, <i>MEIOB</i>, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency. Cancer Biology and Medicine, 2021, 18, 74-87.	1.4	7
1051	Functional Motifs of the Androgen Receptor. , 2009, , 241-267.		4
1052	Intrathymic Selection: New Insight into Tumor Immunology. Advances in Experimental Medicine and Biology, 2007, 601, 133-144.	0.8	6
1053	Cancer/Testis Antigens: Potential Targets for Immunotherapy. , 2012, , 347-369.		10
1054	DNA Hypomethylation and Activation of Germline-Specific Genes in Cancer. Advances in Experimental Medicine and Biology, 2013, 754, 149-166.	0.8	41

#	ARTICLE	IF	CITATIONS
1055	Dendritic Cells and Peptide-Based Vaccine In Multiple Myeloma. , 2013, , 131-154.		1
1056	Lamina-Associated Polypeptide (LAP)2 [±] and Other LEM Proteins in Cancer Biology. Advances in Experimental Medicine and Biology, 2014, 773, 143-163.	0.8	40
1057	Using RNA Sequencing to Characterize the Tumor Microenvironment. Methods in Molecular Biology, 2020, 2055, 245-272.	0.4	3
1058	From Basic Immunology to New Therapies for Cancer Patients. , 2014, , 3-11.		3
1059	Life-Cycle Features of Tumour Cells. , 2008, , 61-71.		3
1061	The Embryonic Rest Hypothesis of Cancer Development: 150 Years Later. , 2013, , 51-63.		5
1062	Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer. Asian Journal of Andrology, 2012, 14, 400-404.	0.8	14
1063	Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms. Cellular and Molecular Immunology, 2020, 17, 576-586.	4.8	12
1065	Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. OncoImmunology, 2021, 10, 1856545.	2.1	13
1072	Profiling cancer testis antigens in non-“small-cell lung cancer. JCI Insight, 2016, 1, e86837.	2.3	82
1073	SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. Journal of Clinical Investigation, 2005, 116, 90-100.	3.9	153
1074	Egress of sperm autoantigen from seminiferous tubules maintains systemic tolerance. Journal of Clinical Investigation, 2017, 127, 1046-1060.	3.9	93
1075	Evolutionary Diversification of SPANX-N Sperm Protein Gene Structure and Expression. PLoS ONE, 2007, 2, e359.	1.1	37
1076	Spermatogenesis Associated Retrogenes Are Expressed in the Human Ovary and Ovarian Cancers. PLoS ONE, 2009, 4, e5064.	1.1	21
1077	The Expansion of the PRAME Gene Family in Eutheria. PLoS ONE, 2011, 6, e16867.	1.1	39
1078	MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer. PLoS ONE, 2011, 6, e21366.	1.1	47
1079	MAGE I Transcription Factors Regulate KAP1 and KRAB Domain Zinc Finger Transcription Factor Mediated Gene Repression. PLoS ONE, 2011, 6, e23747.	1.1	40
1080	NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycytabine. PLoS ONE, 2012, 7, e32165.	1.1	52

#	ARTICLE	IF	CITATIONS
1081	Distinct DNA Methylation Dynamics of Spermatogenic Cell-Specific Intronless Genes Is Associated with CpG Content. PLoS ONE, 2012, 7, e43658.	1.1	6
1082	Melanoma-Associated Cancer-Testis Antigen 16 (CT16) Regulates the Expression of Apoptotic and Antiapoptotic Genes and Promotes Cell Survival. PLoS ONE, 2012, 7, e45382.	1.1	18
1083	MAGEB2 is Activated by Promoter Demethylation in Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2012, 7, e45534.	1.1	27
1084	Differential Evolution of MAGE Genes Based on Expression Pattern and Selection Pressure. PLoS ONE, 2012, 7, e48240.	1.1	24
1085	Centrosomal Localisation of the Cancer/Testis (CT) Antigens NY-ESO-1 and MAGE-C1 Is Regulated by Proteasome Activity in Tumour Cells. PLoS ONE, 2013, 8, e83212.	1.1	8
1086	Development of a T Cell Receptor Targeting an HLA-A*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 for Adoptive Immunotherapy of Cancer. PLoS ONE, 2014, 9, e93321.	1.1	19
1087	Retrotransposon Hypomethylation in Melanoma and Expression of a Placenta-Specific Gene. PLoS ONE, 2014, 9, e95840.	1.1	11
1088	Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e104099.	1.1	65
1089	Differential Antigen Expression Profile Predicts Immunoreactive Subset of Advanced Ovarian Cancers. PLoS ONE, 2014, 9, e111586.	1.1	10
1090	Genome-Wide DNA Methylation Analysis Identifies Novel Hypomethylated Non-Pericentromeric Genes with Potential Clinical Implications in ICF Syndrome. PLoS ONE, 2015, 10, e0132517.	1.1	33
1091	Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer. PLoS ONE, 2015, 10, e0134967.	1.1	11
1092	Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients. PLoS ONE, 2016, 11, e0150623.	1.1	4
1093	Placenta-Enriched LincRNAs MIR503HG and LINC00629 Decrease Migration and Invasion Potential of JEG-3 Cell Line. PLoS ONE, 2016, 11, e0151560.	1.1	36
1094	TFDP3 Regulates Epithelial-Mesenchymal Transition in Breast Cancer. PLoS ONE, 2017, 12, e0170573.	1.1	5
1095	DNA methylation of the Fthl17 5'UTR upstream region regulates differential Fthl17 expression in lung cancer cells and germline stem cells. PLoS ONE, 2017, 12, e0172219.	1.1	4
1096	Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer. Tumori, 2014, 100, 60-8.	0.6	16
1098	EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE. Uspehi Molekularnoj Onkologii, 2018, 5, 62-70.	0.1	2
1099	Gene and miRNA expression changes in squamous cell carcinoma of larynx and hypopharynx. Genes and Cancer, 2015, 6, 328-340.	0.6	23

#	ARTICLE	IF	CITATIONS
1100	Expression of Cancer/Testis genes in ductal carcinoma in situ and benign lesions of the breast. <i>Oncoscience</i> , 2013, 1, 14-20.	0.9	13
1101	Identification of a class of human cancer germline genes with transcriptional silencing refractory to the hypomethylating drug 5-aza-2'-deoxycytidine. <i>Oncoscience</i> , 2014, 1, 745-750.	0.9	12
1102	The "melanoma-enriched"™ microRNA miR-4731-5p acts as a tumour suppressor. <i>Oncotarget</i> , 2016, 7, 49677-49687.	0.8	21
1103	Copy number gain of VCX, X-linked multi-copy gene, leads to cell proliferation and apoptosis during spermatogenesis. <i>Oncotarget</i> , 2016, 7, 78532-78540.	0.8	11
1104	CD147 regulates extrinsic apoptosis in spermatocytes by modulating NF- κ B signaling pathways. <i>Oncotarget</i> , 2017, 8, 3132-3143.	0.8	24
1105	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 14719-14735.	0.8	21
1106	KIAA1114, a full-length protein encoded by the trophinin gene, is a novel surface marker for isolating tumor-initiating cells of multiple hepatocellular carcinoma subtypes. <i>Oncotarget</i> , 2014, 5, 1226-1240.	0.8	14
1107	The clinical value, regulatory mechanisms, and gene network of the cancer-testis gene <i>STK31</i> in pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 35154-35164.	0.8	3
1108	Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. <i>Oncotarget</i> , 2014, 5, 1052-1061.	0.8	35
1109	The downregulation of putative anticancer target BORIS/CTCFL in an addicted myeloid cancer cell line modulates the expression of multiple protein coding and ncRNA genes. <i>Oncotarget</i> , 2017, 8, 73448-73468.	0.8	4
1110	Systematic identification of long non-coding RNAs with cancer-testis expression patterns in 14 cancer types. <i>Oncotarget</i> , 2017, 8, 94769-94779.	0.8	10
1111	Expression of TDRD9 in a subset of lung carcinomas by CpG island hypomethylation protects from DNA damage. <i>Oncotarget</i> , 2018, 9, 9618-9631.	0.8	29
1112	MAGE-A11 is activated through TFCP2/ZEB1 binding sites de-methylation as well as histone modification and facilitates ESCC tumor growth. <i>Oncotarget</i> , 2018, 9, 3365-3378.	0.8	16
1113	Expression dynamics of <i>Mage</i> family genes during self-renewal and differentiation of mouse pluripotent stem and teratocarcinoma cells. <i>Oncotarget</i> , 2019, 10, 3248-3266.	0.8	11
1114	Cancer-testis antigens MAGEA proteins are incorporated into extracellular vesicles released by cells. <i>Oncotarget</i> , 2019, 10, 3694-3708.	0.8	7
1115	AKAP4 is a circulating biomarker for non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 17637-17647.	0.8	34
1116	Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. <i>Oncotarget</i> , 2015, 6, 30194-30211.	0.8	14
1117	Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes. <i>Oncotarget</i> , 2012, 3, 843-853.	0.8	50

#	ARTICLE	IF	CITATIONS
1118	Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E. <i>Oncotarget</i> , 2015, 6, 42028-42039.	0.8	27
1119	High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 4871-4881.	0.8	18
1120	The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion. <i>Oncotarget</i> , 2016, 7, 14708-14726.	0.8	47
1121	Effects of CT-Xp Gene Knock down in Melanoma Cell Lines. <i>Oncotarget</i> , 2013, 4, 531-541.	0.8	23
1122	The prevalence and expression pattern of melanoma-associated antigen 1 in esophageal squamous cell carcinoma: a historical cohort study. <i>Electronic Physician</i> , 2017, 9, 3756-3763.	0.2	8
1123	Targeted Drug Delivery for Breast Cancer Treatment. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2013, 8, 143-153.	0.8	26
1124	Long Non Coding RNA Expression Intersecting Cancer and Spermatogenesis: A Systematic Review. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 2601-2610.	0.5	22
1125	Cancer/Testis genes in relation to sperm biology and function. <i>Iranian Journal of Basic Medical Sciences</i> , 2017, 20, 967-974.	1.0	15
1126	Immunotherapy and potential molecular targets for the treatment of pituitary adenomas resistant to standard therapy: a critical review of potential therapeutic targets and current developments. <i>Journal of Neurosurgical Sciences</i> , 2020, 64, 71-83.	0.3	7
1127	Somatic role of SYCE2: an insulator that dissociates HP1± from H3K9me3 and potentiates DNA repair. <i>Life Science Alliance</i> , 2018, 1, e201800021.	1.3	4
1128	Expression of Cancer-Testis Genes in Brain Tumors. <i>Journal of Korean Neurosurgical Society</i> , 2008, 43, 190.	0.5	18
1129	Cancer/Testis Antigen HCA587-Derived Long Peptide Vaccine Generates Potent Immunologic Responses and Antitumor Effects in Mouse Model. <i>Oncology Research</i> , 2014, 21, 193-200.	0.6	7
1130	Cancer/testis antigens and obligate participation in multiple hallmarks of cancer: an update. <i>Asian Journal of Andrology</i> , 2016, 18, 711.	0.8	4
1131	Prostate-associated gene 4 (PAGE4), an intrinsically disordered cancer/testis antigen, is a novel therapeutic target for prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 695.	0.8	19
1132	Characterization of MAGEG2 with testis-specific expression in mice. <i>Asian Journal of Andrology</i> , 2017, 19, 659.	0.8	8
1133	Targeting cancer testis antigens for biomarkers and immunotherapy in colorectal cancer: Current status and challenges. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 492.	0.8	19
1134	Current status of cancer immunotherapy. <i>Journal of Stem Cells and Regenerative Medicine</i> , 2014, 10, 8-13.	2.2	17
1135	Expression of the Brother of the Regulator of Imprinted Sites Gene in the Sputum of Patients with Lung Cancer. <i>Korean Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 47, 378-383.	0.6	2

#	ARTICLE	IF	CITATIONS
1136	Promoter demethylation mediates the expression of ZNF645, a novel cancer/testis gene. BMB Reports, 2010, 43, 400-406.	1.1	5
1137	Expression of Testis Specific Genes TSGA10, TEX101 and ODF3 in Breast Cancer. Iranian Red Crescent Medical Journal, 2012, 14, 730-4.	0.5	42
1138	Cellular Heterogeneity in Vertical Growth Phase Melanoma. Archives of Pathology and Laboratory Medicine, 2010, 134, 1750-1757.	1.2	24
1139	Gene targeting in melanoma therapy: exploiting of surface markers and specific promoters. Biopolymers and Cell, 2012, 28, 3-13.	0.1	3
1140	Cancer/Testis OIP5 and TAF7L Genes are Up-Regulated in Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4623-4628.	0.5	20
1141	Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression. ELife, 2020, 9, .	2.8	16
1142	The testis protein ZNF165 is a SMAD3 cofactor that coordinates oncogenic TGF β 2 signaling in triple-negative breast cancer. ELife, 2020, 9, .	2.8	21
1143	Meta-analysis of microarray datasets identify several chromosome segregation-related cancer/testis genes potentially contributing to anaplastic thyroid carcinoma. PeerJ, 2018, 6, e5822.	0.9	11
1145	Development of a novel embryonic germline gene-related prognostic model of lung adenocarcinoma. PeerJ, 2021, 9, e12257.	0.9	0
1146	Pathogenicity of the MAGE family (Review). Oncology Letters, 2021, 22, 844.	0.8	10
1148	SEREX; discovery of tumor antigens. Journal of Life Science, 2007, 17, 841-846.	0.2	2
1149	Prognostic Impact of Cancer Testis Antigens Expression in Advanced Stage Multiple Myeloma Patients.. Blood, 2007, 110, 4733-4733.	0.6	6
1150	Factoring in Antigen Processing in Designing Antitumor T-Cell Vaccines. Translational Medicine Series, 2008, , 1-30.	0.0	0
1151	Role of DNA Methylation in Cancer Progression. , 2008, , 79-93.		0
1152	Cancer Genes, Genomes, and the Environment. , 2009, , 808-817.		0
1154	Gene Content of the Mammalian X Chromosome. , 2010, , 173-185.		0
1156	Extending the Use of Adoptive T Cell Immunotherapy for Infections and Cancer. , 2011, , 3-33.		0
1157	Cancer Germline Antigens. , 2011, , 623-626.		0

#	ARTICLE	IF	CITATIONS
1158	GAGE Proteins. , 2011, , 1485-1486.		0
1159	Review of Cancer-Testis (CT) Genes. Journal of Life Science, 2011, 21, 912-922.	0.2	0
1160	Recombinant protein vaccination for antigen-specific cancer immunotherapy. , 2011, , 87-102.		0
1161	Adoptive Immunotherapy of Melanoma. , 2012, , 439-465.		0
1162	Epigenetic Biomarkers in Melanoma. , 2012, , 89-112.		0
1163	SSX2 (Synovial Sarcoma, X breakpoint 2). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
1164	Are Cancer-Testis Antigens Cancer Stem Cell Markers?. Single Cell Biology, 2012, 01, .	0.2	0
1165	Principles of tumor immunology. , 2013, , 925-934.		0
1167	PAD Enzymes in Female Reproductive Tissues and Cancer Pathogenesis. , 2014, , 305-326.		1
1168	Heat-Shock Protein-Based Cancer Immunotherapy. , 2014, , 37-56.		0
1169	Cancer Germline Antigens. , 2014, , 1-4.		0
1170	Cancer Germline Antigens. , 2014, , 759-762.		0
1171	Vaccine Therapy for Pancreatic Cancer: A Battle against Deadly Cancer. Journal of Cancer Science & Therapy, 2014, 06, .	1.7	1
1174	IMMUNOGENIC CANCER-TESTIS ANTIGENS AND THEIR GENES IN MALIGNANT TUMORS. , 2015, 14, 31-38.	0.3	0
1175	Tumor Immunology and Immunotherapy in Cancer Patients. , 2016, , 425-442.		2
1176	GAGE Proteins. , 2016, , 1827-1828.		0
1177	Expression Analysis of ARMC3, a Testis-Specific Gene, in Breast Cancer Patients. Biotechnology and Health Sciences, 2016, 3, .	0.3	1
1178	Molecular Pathogenesis of Prostate Cancer. , 2017, , 171-189.		0

#	ARTICLE	IF	CITATIONS
1179	Cancer Epigenomics on Precision Medicine and Immunotherapy. , 2017, , 1-21.		0
1183	Advances of LncRNA in Lung Cancer. <i>Advances in Clinical Medicine</i> , 2018, 08, 915-921.	0.0	0
1186	Cellular Immunotherapy for Sarcomas. , 2019, , 139-152.		0
1189	Harnessing the Immune System to Target Cancer Cells. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 137-151.	0.1	0
1190	Anticancer Immunotherapy: Prospects and Challenges. , 2019, , 189-228.		0
1194	Deletion of the PDZ-binding kinase (Pbk) gene does not affect male fertility in mice. <i>Reproduction, Fertility and Development</i> , 2020, 32, 893.	0.1	2
1197	Role of purinergic system and vitamin D in the anti-cancer immune response. <i>Life Sciences</i> , 2021, 287, 120110.	2.0	5
1198	Cancer-testis antigen MAGE-C1/â€ŠCT7 in multiple myeloma: literature review. <i>Oncogematologiya</i> , 2020, 15, 29-37.	0.1	0
1199	Emerging Meningioma Therapies II: Immunotherapies, Novel Radiotherapy Techniques, and Other Experimental Approaches. , 2020, , 227-238.		0
1200	Minimal Residual Disease in Melanoma:molecular characterization of in transit cutaneous metastases and Circulating Melanoma Cells recognizes an expression panel potentially related to disease progression. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100262.	0.7	2
1201	Immunopathology of Specific Cancers in Males and Females and Immunotherapy of Prostate and Cervical Cancer. , 2020, , 475-486.		0
1202	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
1203	Myeloidâ€Šderived suppressor cells infiltration in nonâ€Šsmallâ€Šcell lung cancer tumor and MAGEâ€ŠA4 and NYâ€ŠESOâ€Š1 expression. <i>Oncology Letters</i> , 2020, 19, 3982-3992.	0.8	3
1206	Integration Analysis of m6A Related Genes in Skin Cutaneous Melanoma and the Biological Function Research of the SPRR1B. <i>Frontiers in Oncology</i> , 2021, 11, 729045.	1.3	7
1207	A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications. <i>British Journal of Cancer</i> , 2022, 126, 238-246.	2.9	24
1208	A New Generation of Vaccines in the Age of Immunotherapy. <i>Current Oncology Reports</i> , 2021, 23, 137.	1.8	11
1210	Computational Inference of Gene Regulation from Whole-Transcriptome Analysis of Early Embryos. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 0, , 241-279.	0.3	0
1211	Dendritic Cell Vaccines. , 2007, , 251-274.		0

#	ARTICLE	IF	CITATIONS
1213	Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. <i>Croatian Medical Journal</i> , 2006, 47, 32-41.	0.2	33
1214	BORIS/CTCF expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. <i>Cancer Immunity</i> , 2010, 10, 6.	3.2	20
1215	Cancer is a somatic cell pregnancy. <i>Cancer Immunity</i> , 2007, 7, 19.	3.2	36
1216	Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. <i>Cancer Immunity</i> , 2007, 7, 11.	3.2	71
1217	PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. <i>Cancer Immunity</i> , 2007, 7, 18.	3.2	51
1218	Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. <i>Cancer Immunity</i> , 2007, 7, 12.	3.2	102
1219	DNA methylation-dependent regulation of BORIS/CTCF expression in ovarian cancer. <i>Cancer Immunity</i> , 2007, 7, 21.	3.2	76
1220	T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. <i>Cancer Immunity</i> , 2007, 7, 9.	3.2	87
1221	Expression of cancer-testis (CT) antigens in placenta. <i>Cancer Immunity</i> , 2007, 7, 15.	3.2	49
1222	Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine. <i>Cancer Immunity</i> , 2009, 9, 9.	3.2	6
1223	Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. <i>Cancer Immunity</i> , 2009, 9, 6.	3.2	31
1224	Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient. <i>Cancer Immunity</i> , 2009, 9, 8.	3.2	10
1225	Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. <i>Cancer Immunity</i> , 2008, 8, 8.	3.2	10
1226	Cancer-testis (CT) antigen expression in medulloblastoma. <i>Cancer Immunity</i> , 2008, 8, 7.	3.2	40
1227	Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens. <i>Cancer Immunity</i> , 2008, 8, 13.	3.2	15
1228	Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer. <i>Cancer Immunity</i> , 2008, 8, 11.	3.2	24
1229	Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. <i>Cancer Immunity</i> , 2008, 8, 2.	3.2	76
1230	A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. <i>Cancer Immunity</i> , 2010, 10, 8.	3.2	33

#	ARTICLE	IF	CITATIONS
1231	Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. <i>Cancer Immunity</i> , 2010, 10, 1.	3.2	32
1232	Cancer/testis (CT) antigens are expressed in fetal ovary. <i>Cancer Immunity</i> , 2007, 7, 1.	3.2	35
1233	Cancer-testis antigens: the current status on antigen regulation and potential clinical use. <i>American Journal of Blood Research</i> , 2012, 2, 29-35.	0.6	26
1234	BORIS/CTCF mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. <i>Cancer Immunity</i> , 2013, 13, 6.	3.2	18
1236	Chromosome X-encoded Cancer/Testis antigens are less frequently expressed in non-seminomatous germ cell tumors than in seminomas. <i>Cancer Immunity</i> , 2013, 13, 10.	3.2	3
1237	Rethinking immunotherapy for brain cancers in the light of cancer complexity. <i>Indian Journal of Medical Research</i> , 2013, 137, 871-3.	0.4	0
1238	Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 4112-9.	0.5	5
1239	Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 6734-42.	0.5	28
1240	MOK overexpression is associated with promoter hypomethylation in patients with acute myeloid leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 127-36.	0.5	4
1241	Histological and immunohistochemical markers for progression prediction in transurethral resected high-grade non-muscle invasive bladder cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 743-50.	0.5	12
1242	Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIa non-small cell lung cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5509-18.	0.5	13
1243	Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 7786-97.	0.5	10
1244	AKAP4 mediated tumor malignancy in esophageal cancer. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 597-605.	0.0	9
1245	Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer. <i>Iranian Journal of Public Health</i> , 2016, 45, 1618-1624.	0.3	5
1246	Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases. <i>Oncology Letters</i> , 2017, 14, 6485-6496.	0.8	5
1247	Optimizing peptide epitope-based autoantibody detection in cancer patients. <i>American Journal of Clinical and Experimental Immunology</i> , 2017, 6, 84-91.	0.2	0
1248	Ectopic Expression of Human Gene in ESCC Cell Line Using Retroviral System. <i>Avicenna Journal of Medical Biotechnology</i> , 2018, 10, 75-82.	0.2	1
1250	Expression of Human Placenta-specific 1 (PLAC1) in CHO-K1 Cells. <i>Avicenna Journal of Medical Biotechnology</i> , 2020, 12, 24-31.	0.2	0

#	ARTICLE	IF	CITATIONS
1251	MAGEA3 promotes proliferation and suppresses apoptosis in cervical cancer cells by inhibiting the KAP1/p53 signaling pathway. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 3596-3612.	0.0	5
1252	The expression, modulation and use of cancer-testis antigens as potential biomarkers for cancer immunotherapy. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 7002-7019.	0.0	9
1253	Is There a Role for Immunotherapy in Central Nervous System Cancers?. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 237-252.	0.9	5
1254	Cancer Vaccine in Solid Tumors: Where We Stand. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 319-324.	0.1	0
1255	Role and Clinical Utility of Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5690.	1.7	3
1256	Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. <i>Nature Cancer</i> , 2021, 2, 1224-1242.	5.7	37
1257	Repression of germline genes by PRC1.6 and SETDB1 in the early embryo precedes DNA methylation-mediated silencing. <i>Nature Communications</i> , 2021, 12, 7020.	5.8	26
1258	Dissecting the functional pleiotropism of lysine demethylase 5B in physiology and pathology. <i>Journal of Cancer Research and Practice</i> , 2020, 7, 49.	0.2	0
1259	Cancer testis antigen XAGE-1 is a promising marker for the diagnosis and treatment of ovarian cancer. <i>Journal of Medicine and Life</i> , 2021, 14, 710-715.	0.4	0
1260	Immune Landscape and Role of Immunotherapy in Treatment of HPV-Associated Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Otorhinolaryngology Reports</i> , 2022, 10, 96-107.	0.2	0
1261	Antitumor Peptide-Based Vaccine in the Limelight. <i>Vaccines</i> , 2022, 10, 70.	2.1	10
1262	Hypomethylation-activated cancer-testis gene LIN28B promotes cell proliferation and metastasis in gastric cancer. <i>Gene</i> , 2022, 813, 146115.	1.0	6
1263	Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e21.	1.6	21
1264	Unifying heterogeneous expression data to predict targets for CAR-T cell therapy. <i>OncolImmunology</i> , 2021, 10, 2000109.	2.1	1
1265	The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription. <i>Nature Cancer</i> , 2022, 3, 203-218.	5.7	38
1266	A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 809761.	2.2	29
1267	Genome-Wide Association Analyses Identify <i>CATSPERE</i> as a Mediator of Colorectal Cancer Susceptibility and Progression. <i>Cancer Research</i> , 2022, 82, 986-997.	0.4	3
1268	Differential gene expression and network analysis in head and neck squamous cell carcinoma. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 1361-1370.	1.4	3

#	ARTICLE	IF	CITATIONS
1269	Adoptive T-cell Immunotherapy: Perfecting Self-Defenses. <i>Experientia Supplementum</i> (2012), 2022, 113, 253-294.	0.5	1
1270	Adjuvants for improving cancer vaccines. , 2022, , 209-226.		0
1271	Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances. <i>Advances in Cancer Research</i> , 2022, , .	1.9	2
1272	The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges. <i>Biomedicines</i> , 2022, 10, 468.	1.4	1
1273	Comprehensive analysis of SPAG1 expression as a prognostic and predictive biomarker in acute myeloid leukemia by integrative bioinformatics and clinical validation. <i>BMC Medical Genomics</i> , 2022, 15, 38.	0.7	2
1274	A Novel Multiepitope Vaccine Against Bladder Cancer Based on CTL and HTL Epitopes for Induction of Strong Immune Using Immunoinformatics Approaches. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 71.	0.9	3
1275	Identification of MAGEC2/CT10 as a High Calcium-Inducible Gene in Triple-Negative Breast Cancer. <i>Frontiers in Endocrinology</i> , 2022, 13, 816598.	1.5	0
1276	The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the PTEN/PI3K/AKT/mTOR signaling. <i>Bioengineered</i> , 2022, 13, 8478-8489.	1.4	6
1277	Long Non-Coding RNA-Based Functional Prediction Reveals Novel Targets in Notch-Upregulated Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1557.	1.7	2
1278	Development of Peptide-Based Vaccines for Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	32
1279	Novel Immunotherapies for Osteosarcoma. <i>Frontiers in Oncology</i> , 2022, 12, 830546.	1.3	25
1280	Differential expression of preferentially expressed antigen in melanoma (PRAME) in testicular germ cell tumors " A comparative study with SOX17. <i>Experimental and Molecular Pathology</i> , 2022, 126, 104761.	0.9	4
1281	Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 7142.	5.8	21
1282	miR-154 Influences HNSCC Development and Progression through Regulation of the Epithelial-to-Mesenchymal Transition Process and Could Be Used as a Potential Biomarker. <i>Biomedicines</i> , 2021, 9, 1894.	1.4	2
1283	Immunological responses to adjuvant vaccination with combined CD1c ⁺ myeloid and plasmacytoid dendritic cells in stage III melanoma patients. <i>Oncolmmunology</i> , 2022, 11, .	2.1	14
1284	High expression of MAGE-C1 gene in colorectal cancer is associated with its poor prognosis. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2872-2881.	0.6	4
1285	NK cell upraise in the dark world of cancer stem cells. <i>Cancer Cell International</i> , 2021, 21, 682.	1.8	9
1286	Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. <i>The Cochrane Library</i> , 2021, 2021, CD011300.	1.5	8

#	ARTICLE	IF	CITATIONS
1287	<i>MAGE-C1</i> gene and mage-c1 protein expression comparison in primary multiple myeloma patients. <i>Oncogematologiya</i> , 2022, 17, 51-59.	0.1	0
1288	Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers. <i>Pharmaceutics</i> , 2022, 14, 867.	2.0	9
1289	Mendelian nightmares: the germline-restricted chromosome of songbirds. <i>Chromosome Research</i> , 2022, 30, 255-272.	1.0	11
1290	Noncanonical functions of PIWIL1/piRNAs in animal male germ cells and human diseases. <i>Biology of Reproduction</i> , 2022, 107, 101-108.	1.2	8
1302	Discovery and Structural Basis of the Selectivity of Potent Cyclic Peptide Inhibitors of MAGE-A4. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 7231-7245.	2.9	12
1303	Thymic and extrathymic <i>Aire</i> -expressing cells in maternal-fetal tolerance. <i>Immunological Reviews</i> , 2022, , .	2.8	2
1304	Therapeutic bispecific antibodies against intracellular tumor antigens. <i>Cancer Letters</i> , 2022, 538, 215699.	3.2	12
1306	Systems-Level Mapping of Cancer Testis Antigen 1b/a to Sarcoma Pathways Identifies Activated Ran Binding-2 E3 SUMO-Protein Ligase and Transducin-Like Enhancer Protein 1. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	0
1307	Exposed and Sequestered Antigens in Testes and Their Protection by Regulatory T Cell-Dependent Systemic Tolerance. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	0
1308	Serum Biomarker Panel for Rapid Early Diagnosis of Lung Cancer. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	2
1310	Meiotic chromosome organization and its role in recombination and cancer. <i>Current Topics in Developmental Biology</i> , 2022, , .	1.0	1
1311	Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides. <i>Cell Reports</i> , 2022, 39, 110916.	2.9	28
1312	Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1): A Promising Cancer Testis Antigen. , 2022, 13, 1267.		4
1313	Targeting the Epigenome in Malignant Melanoma: Facts, Challenges and Therapeutic Promises. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1314	Epigenomics in Malignant Pleural Mesothelioma. , 0, , .		0
1315	Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3216.	1.7	4
1316	Immunotherapy of sarcomas with modified T cells. <i>Current Opinion in Oncology</i> , 2022, 34, 362-370.	1.1	5
1317	<i>PRAME</i> expression is similar in scar and desmoplastic melanoma. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 829-832.	0.7	11

#	ARTICLE	IF	CITATIONS
1318	Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy. , 2022, 10, e004600.		0
1319	The Contributions of Cancer-Testis and Developmental Genes to the Pathogenesis of Keratinocyte Carcinomas. <i>Cancers</i> , 2022, 14, 3630.	1.7	4
1320	Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy. <i>Epigenomics</i> , 2022, 14, 865-886.	1.0	0
1321	Therapy-Induced Senescent/Polyploid Cancer Cells Undergo Atypical Divisions Associated with Altered Expression of Meiosis, Spermatogenesis and EMT Genes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8288.	1.8	9
1322	A maternal high-fat diet induces fetal origins of NASH-HCC in mice. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1323	Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine. <i>Investigational New Drugs</i> , 2022, 40, 1173-1184.	1.2	6
1324	Polyploidy as an Adaptation against Loss of Heterozygosity in Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8528.	1.8	4
1325	Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application. <i>Cancer Letters</i> , 2022, 546, 215840.	3.2	13
1326	Igniting Hope for Tumor Immunotherapy: Promoting the "Hot and Cold" Tumor Transition. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211207.	0.6	11
1327	Epigenetic Mediated Regulation of Cancer-Testis/Germline Antigen and Its Implication in Cancer Immunotherapy: A Treasure Map for Future Anticipatory Medicine. <i>Cognitive Systems Monographs</i> , 2022, , 149-166.	0.1	0
1328	FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits. <i>Cancer Research</i> , 2022, 82, 2980-3001.	0.4	7
1329	PRAMEY: A Bovid-Specific Y-Chromosome Multicopy Gene Is Highly Related to Postnatal Testicular Growth in Hu Sheep. <i>Animals</i> , 2022, 12, 2380.	1.0	2
1330	Emerging roles and functional mechanisms of PIWI-interacting RNAs. <i>Nature Reviews Molecular Cell Biology</i> , 2023, 24, 123-141.	16.1	62
1331	MND1 functions as a potential prognostic biomarker associated with cell cycle and immune infiltration in kidney renal clear cell carcinoma. <i>Aging</i> , 2022, 14, 7416-7442.	1.4	3
1332	Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy. <i>Cancer Discovery</i> , 2023, 13, 132-145.	7.7	19
1333	Virtual Screening and Quantitative Structure-Activity Relationship of <i>Moringa oleifera</i> with Melanoma Antigen A (MAGE-A) Genes against the Therapeutics of Non-Small Cell Lung Cancers (NSCLCs). <i>Cancers</i> , 2022, 14, 5052.	1.7	2
1334	How germline genes promote malignancy in cancer cells. <i>BioEssays</i> , 2023, 45, .	1.2	4
1335	Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors. <i>Clinical Cancer Research</i> , 2023, 29, 697-704.	3.2	5

#	ARTICLE	IF	CITATIONS
1336	Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. , 2022, 240, 108301.		9
1337	Immunotherapy in gynecologic malignancies. , 2023, , 506-520.e7.		0
1338	Meiotic nuclear divisions 1 promotes proliferation and metastasis in hepatocellular carcinoma and is a potential diagnostic and therapeutic target gene. , 2023, 40, .		0
1339	Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric/Gastroesophageal Junction Cancer. <i>Advanced Science</i> , 2023, 10, .	5.6	6
1340	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. <i>Advances in Clinical Chemistry</i> , 2022, , .	1.8	0
1341	MAGE-I proteins and cancer-pathways: A bidirectional relationship. <i>Biochimie</i> , 2023, 208, 31-37.	1.3	1
1342	The therapeutic potential value of Cancer-testis antigens in immunotherapy of gastric cancer. <i>Gene</i> , 2023, 853, 147082.	1.0	1
1343	Activation of embryonic/germ cell-like axis links poor outcomes of gliomas. <i>Cancer Cell International</i> , 2022, 22, .	1.8	1
1344	Genes that are Used Together are More Likely to be Fused Together in Evolution by Mutational Mechanisms: A Bioinformatic Test of the Used-Fused Hypothesis. <i>Evolutionary Biology</i> , 2023, 50, 30-55.	0.5	4
1345	A male germ-cell-specific ribosome controls male fertility. <i>Nature</i> , 2022, 612, 725-731.	13.7	22
1346	Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis. <i>Experimental and Molecular Medicine</i> , 2022, 54, 2107-2117.	3.2	10
1347	Pan-cancer surveys indicate cell cycle-related roles of primate-specific genes in tumors and embryonic cerebrum. <i>Genome Biology</i> , 2022, 23, .	3.8	6
1349	The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cells. <i>Communications Biology</i> , 2023, 6, .	2.0	4
1350	Dynamic antagonism between key repressive pathways maintains the placental epigenome. <i>Nature Cell Biology</i> , 2023, 25, 579-591.	4.6	2
1352	Identification of TSGA10 and GGNBP2 splicing variants in 5' untranslated region with distinct expression profiles in brain tumor samples. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1353	Cancer-testis non-coding RNA LEF1-AS1 regulates the nuclear translocation of PDCD5 and suppresses its interaction with p53 signaling: a novel target for immunotherapy in esophageal squamous cell carcinoma. <i>Carcinogenesis</i> , 0, , .	1.3	0
1354	Application of plasma membrane proteomics to identify cancer biomarkers. , 2023, , 287-317.		0
1355	Inhibitors targeting epigenetic modifications in cancer. , 2023, , 287-324.		0

#	ARTICLE	IF	CITATIONS
1356	<i>HORMAD1</i> overexpression predicts response to anthracycline+cytotoxic chemotherapy and survival in triple-negative breast cancers. <i>Molecular Oncology</i> , 2023, 17, 2017-2028.	2.1	2
1357	The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. , 2023, , 1-32.		0
1358	Investigating the inhibitory and penetrating properties of three novel anticancer and antimicrobial scorpion peptides via molecular docking and molecular dynamic simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-32.	2.0	3
1359	Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer. <i>Cells</i> , 2023, 12, 926.	1.8	8
1360	A Therapeutic Vaccine Targeting Rat BORIS (CTCF) for the Treatment of Rat Breast Cancer Tumors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5976.	1.8	1
1361	Allogeneic offspring produced by induction of PD-L1 in spermatogonial stem cells via self-renewal stimulation. <i>Stem Cell Reports</i> , 2023, 18, 985-998.	2.3	1
1362	Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	3
1363	Tumor immune microenvironment of cutaneous angiosarcoma with cancer testis antigens and the formation of tertiary lymphoid structures. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1364	Combating breast cancer progression through combination therapy with hypomethylating agent and glucocorticoid. <i>IScience</i> , 2023, 26, 106597.	1.9	3
1365	GAGE gene and protein expression profile in cancer patients. , 2023, 22, 10-18.	0.3	0
1366	Drug targeting PIWI like protein-piRNA complex, a novel paradigm in the therapeutic framework of retinoblastoma. , 2023, , 329-386.		0
1381	Immunotherapy for Meningiomas. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 225-234.	0.8	0
1393	Immunotherapy for Melanoma. , 2023, , 1693-1712.		0